BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. The Lancet 2002;359:1734-9. [DOI: 10.1016/s0140-6736(02)08649-x] [Cited by in Crossref: 2274] [Cited by in F6Publishing: 844] [Article Influence: 113.7] [Reference Citation Analysis]
Number Citing Articles
1 Lee B, Liu K, Lin C, Kao C. Risk of acute kidney injury after transarterial chemoembolisation in hepatocellular carcinoma patients: A nationwide population-based cohort study. Eur Radiol 2017;27:4482-9. [DOI: 10.1007/s00330-017-4893-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
2 Zhang Y, Lu Y, Zhang C, Huang D, Wu W, Zhang Y, Shen J, Cai Y, Chen W, Yao W. FSCN‑1 increases doxorubicin resistance in hepatocellular carcinoma through promotion of epithelial-mesenchymal transition. Int J Oncol 2018;52:1455-64. [PMID: 29568938 DOI: 10.3892/ijo.2018.4327] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
3 Paul SB, Sharma H. Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. J Clin Exp Hepatol 2014;4:S112-21. [PMID: 25755602 DOI: 10.1016/j.jceh.2014.03.048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
4 de Baere T, Tselikas L, Deschamps F, Boige V, Ducreux M, Hollebecque A. Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes? Hepat Oncol 2016;3:109-18. [PMID: 30191032 DOI: 10.2217/hep-2015-0001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010;28:3994-4005. [PMID: 20679622 DOI: 10.1200/jco.2010.28.7805] [Cited by in Crossref: 261] [Cited by in F6Publishing: 146] [Article Influence: 21.8] [Reference Citation Analysis]
7 Mulcahy MF. Management of hepatocellular cancer. Curr Treat Options Oncol. 2005;6:423-435. [PMID: 16107245 DOI: 10.1007/s11864-005-0045-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
8 Lee TY, Lin CC, Chen CY, Wang TE, Lo GH, Chang CS, Chao Y. Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial. Medicine (Baltimore). 2017;96:e7655. [PMID: 28906355 DOI: 10.1097/md.0000000000007655] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
9 Munene G, Vauthey JN, Dixon E. Summary of the 2010 AHPBA/SSO/SSAT Consensus Conference on HCC. Int J Hepatol. 2011;2011:565060. [PMID: 21994863 DOI: 10.4061/2011/565060] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
10 Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, Guindi M, Porter G, Kachura JR, Rasuli P, Gill S, Ghali P, Chaudhury P, Siddiqui J, Valenti D, Weiss A, Wong R. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 2011;18:228-40. [PMID: 21980250 DOI: 10.3747/co.v18i5.952] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
11 Ji SK, Cho YK, Ahn YS, Kim MY, Park YO, Kim JK, Kim WT. Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization. Korean J Radiol. 2008;9:534-540. [PMID: 19039270 DOI: 10.3348/kjr.2008.9.6.534] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
12 Durham JD, Ray CE. How I do it: triaging patients with hepatocellular carcinoma. Semin Intervent Radiol 2012;29:64-8. [PMID: 23450921 DOI: 10.1055/s-0032-1302454] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Song MJ. Bae SH, Lee SW, Song DS, Kim HY, Yoo IeR, Choi JI, Lee YJ, Chun HJ, Lee HG, Choi JY, Yoon SK. 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:865-873. [PMID: 23436073 DOI: 10.1007/s00259-013-2366-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
14 Woo HY, Heo J. Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future. Clin Mol Hepatol. 2015;21:344-348. [PMID: 26770921 DOI: 10.3350/cmh.2015.21.4.344] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
15 Jin B, Wang D, Lewandowski RJ, Riaz A, Ryu RK, Sato KT, Larson AC, Salem R, Omary RA. Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma. AJR Am J Roentgenol. 2011;196:919-928. [PMID: 21427346 DOI: 10.2214/AJR.10.4770] [Cited by in Crossref: 40] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
16 Helton WS, Di Bisceglie A, Chari R, Schwartz M, Bruix J. Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2003;7:401-11. [PMID: 12654567 DOI: 10.1016/s1091-255x(02)00161-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
17 Bale R, Putzer D, Schullian P. Local Treatment of Breast Cancer Liver Metastasis.Cancers (Basel). 2019;11. [PMID: 31514362 DOI: 10.3390/cancers11091341] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 10.7] [Reference Citation Analysis]
18 Kulkarni C, Sreekumar KP, Prabhu NK, Kannan RR, Moorthy S. Utility of C-arm CT in overcoming challenges in patients undergoing Transarterial chemoembolization for hepatocellular carcinoma. Indian J Radiol Imaging 2014;24:80-3. [PMID: 24851011 DOI: 10.4103/0971-3026.130709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
19 Kai AK, Chan LK, Lo RC, Lee JM, Wong CC, Wong JC, Ng IO. Down-regulation of TIMP2 by HIF-1α/miR-210/HIF-3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma. Hepatology 2016;64:473-87. [PMID: 27018975 DOI: 10.1002/hep.28577] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 9.0] [Reference Citation Analysis]
20 Li J, Liu W, Zhu W, Wu Y, Wu B. Transcatheter hepatic arterial chemoembolization and sorafenib for hepatocellular carcinoma: a meta-analysis of randomized, double-blind controlled trials. Oncotarget. 2017;8:59601-59608. [PMID: 28938663 DOI: 10.18632/oncotarget.19334] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
21 Chan WH, Huang SF, Lee CW, Wu TH, Pan KT, Lin SM, Yu MC, Hung CF. Incorporation of biochemical factors for survival analysis of transarterial chemoembolization in patients with hepatocellular carcinoma: A retrospective cohort study. J Int Med Res 2019;47:4862-71. [PMID: 31446817 DOI: 10.1177/0300060519866941] [Reference Citation Analysis]
22 Ohki T, Kondo M, Karasawa Y, Kawamura S, Maeshima S, Kojima K, Seki M, Toda N, Shioda Y, Tagawa K. Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index. Adv Ther 2017;34:1097-108. [PMID: 28389996 DOI: 10.1007/s12325-017-0524-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
23 Huang YK, Yen CL, Shiu SI, Lee SW, Chang PY, Yeh HZ, Lee TY. Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma. PLoS One 2017;12:e0188999. [PMID: 29190692 DOI: 10.1371/journal.pone.0188999] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
24 Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010;7:448-58. [PMID: 20628345 DOI: 10.1038/nrgastro.2010.100] [Cited by in Crossref: 810] [Cited by in F6Publishing: 813] [Article Influence: 67.5] [Reference Citation Analysis]
25 Wang P, Sheng L, Wang G, Wang H, Huang X, Yan X, Yang X, Pei R. Association of transarterial chemoembolization with survival in patients with unresectable hepatocellular carcinoma. Mol Clin Oncol 2014;2:203-6. [PMID: 24649333 DOI: 10.3892/mco.2014.239] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kitisin K, Packiam V, Steel J, Humar A, Gamblin TC, Geller DA, Marsh JW, Tsung A. Presentation and outcomes of hepatocellular carcinoma patients at a western centre. HPB (Oxford) 2011;13:712-22. [PMID: 21929672 DOI: 10.1111/j.1477-2574.2011.00362.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
27 Malek NP, Schmidt S, Huber P, Manns MP, Greten TF. The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int 2014;111:101-6. [PMID: 24622679 DOI: 10.3238/arztebl.2014.0101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 32] [Article Influence: 0.7] [Reference Citation Analysis]
28 Kanazawa A, Tsukamoto T, Shimizu S, Kodai S, Yamazoe S, Yamamoto S, Kubo S. Impact of laparoscopic liver resection for hepatocellular carcinoma with F4-liver cirrhosis. Surg Endosc. 2013;27:2592-2597. [PMID: 23392977 DOI: 10.1007/s00464-013-2795-9] [Cited by in Crossref: 72] [Cited by in F6Publishing: 80] [Article Influence: 8.0] [Reference Citation Analysis]
29 Chen J. The prognostic analysis of different metastatic patterns in advanced liver cancer patients: A population based analysis. PLoS One 2018;13:e0200909. [PMID: 30102707 DOI: 10.1371/journal.pone.0200909] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
30 Aboian MS, Yu JF, Gautam A, Sze CH, Yang JK, Chan J, Lillaney PV, Jordan CD, Oh HJ, Wilson DM, Patel AS, Wilson MW, Hetts SW. In vitro clearance of doxorubicin with a DNA-based filtration device designed for intravascular use with intra-arterial chemotherapy. Biomed Microdevices 2016;18:98. [PMID: 27778226 DOI: 10.1007/s10544-016-0124-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
31 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms – Kurzversion 2.00 – Juni 2021, AWMF-Registernummer: 032-053OL. Z Gastroenterol 2022;60:81-107. [PMID: 35042249 DOI: 10.1055/a-1589-7520] [Reference Citation Analysis]
32 Huang M, Lin Q, Wang H, Chen J, Bai M, Wang L, Zhu K, Jiang Z, Guan S, Li Z, Qian J, Li M, Pang P, Shan H. Survival benefit of chemoembolization plus Iodine125 seed implantation in unresectable hepatitis B-related hepatocellular carcinoma with PVTT: a retrospective matched cohort study. Eur Radiol. 2016;26:3428-3436. [PMID: 26792430 DOI: 10.1007/s00330-015-4198-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
33 Shen H, Zheng S, Chen R, Jin X, Xu X, Jing C, Lin J, Zhang J, Zhang M, Zhang L, Xie X, Guo K, Ren Z, Lin S, Zhang B. Prognostic significance of serum procalcitonin in patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization: A retrospective analysis of 509 cases. Medicine (Baltimore) 2017;96:e7438. [PMID: 28700480 DOI: 10.1097/MD.0000000000007438] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Zamora-Valdes D, Taner T, Nagorney DM. Surgical Treatment of Hepatocellular Carcinoma. Cancer Control 2017;24:1073274817729258. [PMID: 28975836 DOI: 10.1177/1073274817729258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
35 Douhara A, Namisaki T, Moriya K, Kitade M, Kaji K, Kawaratani H, Takeda K, Okura Y, Takaya H, Noguchi R, Nishimura N, Seki K, Sato S, Sawada Y, Yamao J, Mitoro A, Uejima M, Mashitani T, Shimozato N, Saikawa S, Nakanishi K, Furukawa M, Kubo T, Yoshiji H. Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization. Oncol Lett 2017;14:3028-34. [PMID: 28927051 DOI: 10.3892/ol.2017.6489] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
36 Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52. [PMID: 19908093 DOI: 10.1007/s00270-099-9711-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Liu Y, Ren Y, Ge S, Xiong B, Zhou G, Feng G, Song S, Zheng C. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome and Risk Signature Analysis. Front Oncol 2021;11:662408. [PMID: 34155478 DOI: 10.3389/fonc.2021.662408] [Reference Citation Analysis]
38 Su TS, Lu HZ, Cheng T, Zhou Y, Huang Y, Gao YC, Tang MY, Jiang HY, Lian ZP, Hou EC, Liang P. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm. BMC Cancer 2016;16:834. [PMID: 27809890 DOI: 10.1186/s12885-016-2894-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
39 Sun L, Fahey P, Zhu X, Ng W, Chen ZP, Qiu Y, Lai H, Lin J, Lin L. A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China. Integr Cancer Ther 2018;17:902-11. [PMID: 29775121 DOI: 10.1177/1534735418775819] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
40 Xu Y, Wang T, Zeng J, Wang B, Zhou L, Yang M, Zhang L, Zhang N. Integrative Functional Genomics Implicated the Key T-/B-Cell Deficiency Regulator RAG1 in Transarterial Chemoembolization of Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:720791. [PMID: 34646823 DOI: 10.3389/fcell.2021.720791] [Reference Citation Analysis]
41 Tajiri K, Futsukaichi Y, Kobayashi S, Nagata K, Yasumura S, Takahara T, Minemura M, Yasuda I. Efficacy of on-demand intrahepatic arterial therapy in combination with sorafenib for advanced hepatocellular carcinoma. Onco Targets Ther 2019;12:2205-14. [PMID: 30988625 DOI: 10.2147/OTT.S191741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers (Basel) 2019;11:E1085. [PMID: 31370248 DOI: 10.3390/cancers11081085] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
43 Gao S, Yang RJ, Dong JH. Hepatocellular carcinoma with blood supply from parasitized omental artery: angiographic appearance and chemoembolization. Chin J Cancer Res 2012;24:207-12. [PMID: 23359452 DOI: 10.1007/s11670-012-0207-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
44 Perera S, Kelly D, O'Kane GM. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease. Curr Oncol 2020;27:S165-72. [PMID: 33343210 DOI: 10.3747/co.27.7159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
45 Hetta WM, Shebria N. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres. The Egyptian Journal of Radiology and Nuclear Medicine 2014;45:761-9. [DOI: 10.1016/j.ejrnm.2014.04.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
46 Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920970840. [PMID: 33224278 DOI: 10.1177/1758835920970840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
47 Kobayashi T, Ishiyama K, Ohdan H. Prevention of recurrence after curative treatment for hepatocellular carcinoma. Surg Today 2013;43:1347-54. [DOI: 10.1007/s00595-012-0473-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
48 Wang G, Liu Y, Zhou SF, Qiu P, Xu L, Wen P, Wen J, Xiao X. Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review. Hepatol Int. 2016;10:501-510. [PMID: 26856326 DOI: 10.1007/s12072-015-9700-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
49 Malagari K, Pomoni M, Moschouris H, Kelekis A, Charokopakis A, Bouma E, Spyridopoulos T, Chatziioannou A, Sotirchos V, Karampelas T. Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study. Cardiovasc Intervent Radiol. 2014;37:165-175. [PMID: 24263774 DOI: 10.1007/s00270-013-0777-x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 7.2] [Reference Citation Analysis]
50 Xie Y, Tian H, Xiang H. Is transcatheter arterial chemoembolization plus sorafenib better than chemoembolization plus placebo in the treatment of hepatocellular carcinoma? Tumori 2021;107:292-303. [PMID: 32729385 DOI: 10.1177/0300891620945029] [Reference Citation Analysis]
51 Buijs M, Vossen JA, Frangakis C, Hong K, Georgiades CS, Chen Y, Liapi E, Geschwind JF. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience. Radiology 2008;249:346-54. [PMID: 18796686 DOI: 10.1148/radiol.2483071902] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
52 Imai Y, Chikayama T, Nakazawa M, Watanabe K, Ando S, Mizuno Y, Yoshino K, Sugawara K, Hamaoka K, Fujimori K. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Gastroenterol. 2011;Epub ahead of print. [PMID: 21976133 DOI: 10.1007/s00535-011-0475-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
53 Li J, Wang Q, Lei Z, Wu D, Si A, Wang K, Wan X, Wang Y, Yan Z, Xia Y, Lau WY, Wu M, Shen F. Adjuvant Transarterial Chemoembolization Following Liver Resection for Intrahepatic Cholangiocarcinoma Based on Survival Risk Stratification. Oncologist. 2015;20:640-647. [PMID: 25956404 DOI: 10.1634/theoncologist.2014-0470] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
54 Lewis AL, Gonzalez MV, Leppard SW, Brown JE, Stratford PW, Phillips GJ, Lloyd AW. Doxorubicin eluting beads - 1: effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med. 2007;18:1691-1699. [PMID: 17483878 DOI: 10.1007/s10856-007-3068-8] [Cited by in Crossref: 121] [Cited by in F6Publishing: 113] [Article Influence: 8.1] [Reference Citation Analysis]
55 Kirichenko A, Gayou O, Parda D, Kudithipudi V, Tom K, Khan A, Abrams P, Szramowski M, Oliva J, Monga D. Stereotactic body radiotherapy (SBRT) with or without surgery for primary and metastatic liver tumors. HPB (Oxford). 2016;18:88-97. [PMID: 26776856 DOI: 10.1016/j.hpb.2015.07.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
56 Sarkar D. AEG-1/MTDH/LYRIC in liver cancer. Adv Cancer Res 2013;120:193-221. [PMID: 23889992 DOI: 10.1016/B978-0-12-401676-7.00007-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
57 Yang L, Zhang XM, Tan BX, Liu M, Dong GL, Zhai ZH. Computed tomographic perfusion imaging for the therapeutic response of chemoembolization for hepatocellular carcinoma. J Comput Assist Tomogr 2012;36:226-30. [PMID: 22446364 DOI: 10.1097/RCT.0b013e318245c23c] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
58 Liapi E, Geschwind JF. Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol. 2011;34:37-49. [PMID: 21069333 DOI: 10.1007/s00270-010-0012-y] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 6.4] [Reference Citation Analysis]
59 An J, Kim HI, Chang S, Shim JH. Continued value of the serum alpha-fetoprotein test in surveilling at-risk populations for hepatocellular carcinoma. PLoS One 2020;15:e0238078. [PMID: 32845895 DOI: 10.1371/journal.pone.0238078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Kudo M. Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer. 2015;4:39-50. [PMID: 26020028 DOI: 10.1159/000367727] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 11.7] [Reference Citation Analysis]
61 Kinugasa H, Nouso K, Takeuchi Y, Yasunaka T, Onishi H, Nakamura S, Shiraha H, Kuwaki K, Hagihara H, Ikeda F. Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma. J Gastroenterol. 2012;47:421-426. [PMID: 22048256 DOI: 10.1007/s00535-011-0492-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
62 Zhuang L, Wen T, Xu M, Yang J, Wang W, Wu H, Zeng Y, Yan L, Wei Y, Li B. Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma. Arch Med Sci 2017;13:1383-93. [PMID: 29181069 DOI: 10.5114/aoms.2017.71066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
63 Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, Del Prete S, Tonini G. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist. 2010;15:85-92. [PMID: 20051477 DOI: 10.1634/theoncologist.2009-0143] [Cited by in Crossref: 120] [Cited by in F6Publishing: 109] [Article Influence: 10.0] [Reference Citation Analysis]
64 Lee S, Kang JH, Kim DY, Ahn SH, Park JY, Kim BK, Kim SU, Han KH. Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. Hepatol Int. 2017;11:292-299. [PMID: 28324324 DOI: 10.1007/s12072-017-9792-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
65 Cheung TT, Kwok PC, Chan S, Cheung CC, Lee AS, Lee V, Cheng HC, Chia NH, Chong CCN, Lai TW, Law ALY, Luk MY, Tong CC, Yau TCC. Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. Liver Cancer 2018;7:40-54. [PMID: 29662832 DOI: 10.1159/000485984] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
66 Najran P, Lamarca A, Mullan D, McNamara MG, Westwood T, Hubner RA, Lawrence J, Manoharan P, Bell J, Valle JW. Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma. Curr Oncol Rep 2017;19:50. [PMID: 28656502 DOI: 10.1007/s11912-017-0603-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
67 Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7:350-391. [PMID: 19406039 DOI: 10.6004/jnccn.2009.0027] [Cited by in Crossref: 299] [Cited by in F6Publishing: 324] [Article Influence: 23.0] [Reference Citation Analysis]
68 Zhang S, Huang C, Li Z, Yang Y, Bao T, Chen H, Zou Y, Song L. Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers. Drug Deliv 2017;24:1011-7. [PMID: 28660787 DOI: 10.1080/10717544.2017.1344336] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
69 Hayano K, Lee SH, Sahani DV. Imaging for assessment of treatment response in hepatocellular carcinoma: Current update. Indian J Radiol Imaging 2015;25:121-8. [PMID: 25969635 DOI: 10.4103/0971-3026.155835] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
70 Cohen GS, Black M. Multidisciplinary management of hepatocellular carcinoma: a model for therapy. J Multidiscip Healthc. 2013;6:189-195. [PMID: 23690690 DOI: 10.2147/jmdh.s41206] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
71 Wu Y, Qi H, Cao F, Shen L, Chen S, Xie L, Huang T, Song Z, Zhou D, Fan W. TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma. Front Pharmacol 2020;11:1130. [PMID: 32903854 DOI: 10.3389/fphar.2020.01130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Vogel A, Gupta S, Zeile M, von Haken R, Brüning R, Lotz G, Vahrmeijer A, Vogl T, Wacker F. Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review. Adv Ther 2017;33:2122-38. [PMID: 27798773 DOI: 10.1007/s12325-016-0424-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
73 Shah RP, Brown KT. Hepatic arterial embolization complicated by acute cholecystitis. Semin Intervent Radiol 2011;28:252-7. [PMID: 22654273 DOI: 10.1055/s-0031-1280675] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
74 Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol. 2012;33:33-40. [PMID: 21931992 DOI: 10.1007/s13277-011-0237-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
75 Xia X, Zhang H, Xia P, Zhu Y, Liu J, Xu K, Yuan Y. Identification of Glycolysis-Related lncRNAs and the Novel lncRNA WAC-AS1 Promotes Glycolysis and Tumor Progression in Hepatocellular Carcinoma. Front Oncol 2021;11:733595. [PMID: 34527595 DOI: 10.3389/fonc.2021.733595] [Reference Citation Analysis]
76 Jianyong L, Lunan Y, Wentao W, Yong Z, Bo L, Tianfu W, Minqing X, Jiaying Y. Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection? Medicine (Baltimore) 2014;93:e180. [PMID: 25474433 DOI: 10.1097/MD.0000000000000180] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
77 Lee S, Kim KA, Park MS, Choi SY. MRI Findings and Prediction of Time to Progression of Patients with Hepatocellular Carcinoma Treated with Drug-eluting Bead Transcatheter Arterial Chemoembolization. J Korean Med Sci 2015;30:965-73. [PMID: 26130962 DOI: 10.3346/jkms.2015.30.7.965] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
78 Kim TH, Park JW, Kim BH, Kim DY, Moon SH, Kim SS, Lee JH, Woo SM, Koh YH, Lee WJ, Kim CM. Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma. Oncotarget. 2017;9:4034-4043. [PMID: 29423102 DOI: 10.18632/oncotarget.23428] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
79 Liu WR, Tian MX, Tao CY, Tang Z, Zhou YF, Song SS, Jiang XF, Wang H, Zhou PY, Qu WF, Fang Y, Ding ZB, Zhou J, Fan J, Shi YH. Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis. BMC Cancer 2020;20:642. [PMID: 32650743 DOI: 10.1186/s12885-020-07138-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Jia Z, Jiang G, Tian F, Zhu C, Qin X. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Saudi J Gastroenterol. 2016;22:353-359. [PMID: 27748320 DOI: 10.4103/1319-3767.191139] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
81 Britten CD, Gomes AS, Wainberg ZA, Elashoff D, Amado R, Xin Y, Busuttil RW, Slamon DJ, Finn RS. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study. BMC Cancer. 2012;12:16. [PMID: 22244160 DOI: 10.1186/1471-2407-12-16] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
82 Pelizzaro F, Haxhi S, Penzo B, Vitale A, Giannini EG, Sansone V, Rapaccini GL, Di Marco M, Caturelli E, Magalotti D, Sacco R, Celsa C, Campani C, Mega A, Guarino M, Gasbarrini A, Svegliati-baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F, Farinati F. Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. Front Oncol 2022;12:822507. [DOI: 10.3389/fonc.2022.822507] [Reference Citation Analysis]
83 Kennedy AS, Sangro B. Nonsurgical treatment for localized hepatocellular carcinoma. Curr Oncol Rep. 2014;16:373. [PMID: 24488546 DOI: 10.1007/s11912-013-0373-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
84 Fairchild AH, White SB. Decision Making in Interventional Oncology: Intra-arterial Therapies for Metastatic Colorectal Cancer-Y90 and Chemoembolization. Semin Intervent Radiol 2017;34:87-91. [PMID: 28579675 DOI: 10.1055/s-0037-1601854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
85 Vossen JA, Buijs M, Geschwind JF, Liapi E, Prieto Ventura V, Lee KH, Bluemke DA, Kamel IR. Diffusion-weighted and Gd-EOB-DTPA-contrast-enhanced magnetic resonance imaging for characterization of tumor necrosis in an animal model. J Comput Assist Tomogr 2009;33:626-30. [PMID: 19638862 DOI: 10.1097/RCT.0b013e3181953df3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
86 Chiang CL, Chan ACY, Chiu KWH, Kong FS. Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy. Front Oncol 2019;9:1157. [PMID: 31799176 DOI: 10.3389/fonc.2019.01157] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
87 Moya Herráiz A, Torres-Quevedo R, Mir Pallardó J. [Liver transplant in patients with hepatocellular carcinoma]. Cir Esp 2008;84:117-24. [PMID: 18783669 DOI: 10.1016/s0009-739x(08)72152-3] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
88 Zhang T, Zhao YT, Wang Z, Li CR, Jin J, Jia AY, Wang SL, Song YW, Liu YP, Ren H, Fang H, Bao H, Liu XF, Yu ZH, Li YX, Wang WH. Efficacy and Safety of Intensity-Modulated Radiotherapy Following Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma. Medicine (Baltimore) 2016;95:e3789. [PMID: 27227954 DOI: 10.1097/MD.0000000000003789] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
89 Kim TH, Park JW, Kim YJ, Kim BH, Woo SM, Moon SH, Kim SS, Koh YH, Lee WJ, Park SJ, Kim JY, Kim DY, Kim CM. Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. Cancer Res Treat. 2015;47:34-45. [PMID: 25381830 DOI: 10.4143/crt.2013.218] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
90 Yim SY, Chun HS, Lee JS, Lim J, Kim TH, Kim BK, Kim SU, Park JY, Ahn SH, Kim GM, Won JY, Seo YS, Kim YH, Um SH, Kim DY. Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients. Cancers 2022;14:385. [DOI: 10.3390/cancers14020385] [Reference Citation Analysis]
91 Somma F, D'Angelo R, Serra N, Gatta G, Grassi R, Fiore F. Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)? PLoS One 2015;10:e0129573. [PMID: 26110810 DOI: 10.1371/journal.pone.0129573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
92 Wiggermann P, Sieron D, Brosche C, Brauer T, Scheer F, Platzek I, Wawrzynek W, Stroszczynski C. Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). Med Sci Monit. 2011;17:CR189-CR195. [PMID: 21455104 DOI: 10.12659/msm.881714] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
93 Fako V, Wang XW. The status of transarterial chemoembolization treatment in the era of precision oncology. Hepat Oncol 2017;4:55-63. [PMID: 28989699 DOI: 10.2217/hep-2017-0009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
94 Gagliardi A, Giuliano E, Venkateswararao E, Fresta M, Bulotta S, Awasthi V, Cosco D. Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors. Front Pharmacol 2021;12:601626. [PMID: 33613290 DOI: 10.3389/fphar.2021.601626] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 17.0] [Reference Citation Analysis]
95 Zhang L, Yin X, Gan YH, Zhang BH, Zhang JB, Chen Y, Xie XY, Ge NL, Wang YH, Ye SL. Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria. BMC Gastroenterol. 2014;14:11. [PMID: 24410841 DOI: 10.1186/1471-230x-14-11] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
96 Huan HB, Wu LL, Lau WY, Wen XD, Zhang L, Yang DP, Wang XS, Bie P, Xia F. Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients' data. Oncotarget 2017;8:90291-300. [PMID: 29163828 DOI: 10.18632/oncotarget.18853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
97 Bouvier A, Ozenne V, Aubé C, Boursier J, Vullierme MP, Thouveny F, Farges O, Vilgrain V. Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. Eur Radiol 2011;21:1719-26. [PMID: 21479978 DOI: 10.1007/s00330-011-2118-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
98 Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776-783; discussion 783-785. [PMID: 15849513 DOI: 10.1097/01.sla.0000161981.58631.ab] [Cited by in Crossref: 250] [Cited by in F6Publishing: 213] [Article Influence: 14.7] [Reference Citation Analysis]
99 Nakano MM, Yamamoto A, Nishida N, Hamuro M, Hamamoto S, Jogo A, Sohgawa E, Kageyama K, Minami T, Miki Y. Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE). Jpn J Radiol 2019;37:543-8. [DOI: 10.1007/s11604-019-00840-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
100 Liem MS, Poon RT, Lo CM, Tso WK, Fan ST. Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation. World J Gastroenterol 2005; 11(29): 4465-4471 [PMID: 16052673 DOI: 10.3748/wjg.v11.i29.4465] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 28] [Article Influence: 1.4] [Reference Citation Analysis]
101 Vilgrain V, Sibert A, Zappa M, Belghiti J. Sequential arterial and portal vein embolization in patients with cirrhosis and hepatocellular carcinoma: the hospital beaujon experience. Semin Intervent Radiol 2008;25:155-61. [PMID: 21326556 DOI: 10.1055/s-2008-1076689] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
102 da Motta-Leal-Filho JM. Locoregional therapies for the treatment of locally advanced hepatocellular carcinoma. Radiol Bras 2021;54:IX-X. [PMID: 34108772 DOI: 10.1590/0100-3984.2021.54.3e3] [Reference Citation Analysis]
103 Ohki T, Sato K, Kondo M, Goto E, Sato T, Kondo Y, Akamatsu M, Sato S, Yoshida H, Koike Y, Obi S. Impact of Adverse Events on the Progression-Free Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Drugs Real World Outcomes 2020;7:141-9. [PMID: 32048238 DOI: 10.1007/s40801-020-00179-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
104 Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391-7400. [PMID: 16437707 DOI: 10.3748/wjg.v11.i47.7391] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 94] [Article Influence: 2.3] [Reference Citation Analysis]
105 Rubinstein MM, Kaubisch A, Kinkhabwala M, Reinus J, Liu Q, Chuy JW. Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation. J Gastrointest Oncol 2017;8:1051-5. [PMID: 29299366 DOI: 10.21037/jgo.2017.08.11] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
106 Müller L, Stoehr F, Mähringer-Kunz A, Hahn F, Weinmann A, Kloeckner R. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. J Hepatocell Carcinoma 2021;8:403-19. [PMID: 34012930 DOI: 10.2147/JHC.S285735] [Reference Citation Analysis]
107 Carr BI. Hepatic artery chemoembolization for hepatocellular carcinoma recurrence confined to the transplanted liver. Case Rep Oncol. 2012;5:506-510. [PMID: 23139662 DOI: 10.1159/000343043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
108 Kawabe N, Hashimoto S, Nakano T, Nakaoka K, Fukui A, Yoshioka K. Transcatheter arterial infusion chemotherapy with cisplatin in combination with transcatheter arterial chemoembolization decreases intrahepatic distant recurrence of unresectable hepatocellular carcinoma. JGH Open 2021;5:705-11. [PMID: 34124389 DOI: 10.1002/jgh3.12573] [Reference Citation Analysis]
109 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2021. [PMID: 34780081 DOI: 10.1111/liv.15101] [Reference Citation Analysis]
110 Das S, Berlin J. Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases. Surg Oncol Clin N Am 2021;30:189-204. [PMID: 33220805 DOI: 10.1016/j.soc.2020.08.008] [Reference Citation Analysis]
111 Ueshima K, Kudo M, Tanaka M, Kumada T, Chung H, Hagiwara S, Inoue T, Yada N, Kitai S. Phase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-Fluorouracil. Liver Cancer 2015;4:263-73. [PMID: 26734580 DOI: 10.1159/000367751] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
112 Park TY, Na YC, Lee WH, Kim JH, Chang WS, Jung HH, Chang JH, Chang JW, Park YG. Treatment Options of Metastatic Brain Tumors from Hepatocellular Carcinoma: Surgical Resection vs. Gamma Knife Radiosurgery vs. Whole Brain Radiation Therapy. Brain Tumor Res Treat 2013;1:78-84. [PMID: 24904896 DOI: 10.14791/btrt.2013.1.2.78] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
113 Vitale A, Navaglia F, Ramírez Morales R, Frigo AC, Basso D, D’Amico F, Zanus G, Bonsignore P, Farinati F, Burra P. Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies. PLoS One. 2011;6:e23093. [PMID: 21912636 DOI: 10.1371/journal.pone.0023093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
114 Li Y, Xu Z, An C, Chen H, Li X. Multi-Task Deep Learning Approach for Simultaneous Objective Response Prediction and Tumor Segmentation in HCC Patients with Transarterial Chemoembolization. JPM 2022;12:248. [DOI: 10.3390/jpm12020248] [Reference Citation Analysis]
115 Bholee AK, Peng K, Zhou Z, Chen J, Xu L, Zhang Y, Chen M. Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. Clin Transl Oncol. 2017;19:844-852. [PMID: 28070766 DOI: 10.1007/s12094-016-1611-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
116 Shaghaghi M, AliyariG Hasabeh M, Ameli S, Ghadimi M, Hazhirkarzar B, Rezvani Habibabadi R, Tang H, Khoshpouri P, Wu Q, Pandey A, Pandey P, Baghdadi A, Kamel IR. Role of tumor margin and ADC change in defining the need for additional treatments after the first TACE in patients with unresectable HCC. Eur J Radiol 2020;133:109389. [PMID: 33166831 DOI: 10.1016/j.ejrad.2020.109389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol 2015; 7(9): 1184-1191 [PMID: 26019734 DOI: 10.4254/wjh.v7.i9.1184] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
118 Torimura T, Iwamoto H, Nakamura T, Koga H, Ueno T, Kerbel RS, Sata M. Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Transl Oncol 2013;6:511-9. [PMID: 24151531 DOI: 10.1593/tlo.13481] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
119 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
120 Zhang J, Xu F, Chen K, Zhou S, Li H, Niu C, Tan X. An effective approach for treating unresectable hepatoblastoma in infants and children: Pre-operative transcatheter arterial chemoembolization. Oncol Lett 2013;6:850-4. [PMID: 24137424 DOI: 10.3892/ol.2013.1444] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
121 Chen ZH, Hong YF, Chen X, Chen J, Lin Q, Lin J, Li X, Wen JY, Ruan DY, Dong M, Wei L, Wang TT, Lin ZX, Ma XK, Wu DH, Wu XY, Xu R. Comparison of five staging systems in predicting the survival rate of patients with hepatocellular carcinoma undergoing trans-arterial chemoembolization therapy. Oncol Lett 2018;15:855-62. [PMID: 29403561 DOI: 10.3892/ol.2017.7419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
122 Abdo AA, Hassanain M, AlJumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, AlMuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J; Saudi Association for the Study of Liver Diseases and Transplantation., Saudi Oncology Society. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012;32:174-99. [PMID: 22366832 DOI: 10.5144/0256-4947.2012.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
123 Dettmer A, Kirchhoff TD, Gebel M, Zender L, Malek NP, Panning B, Chavan A, Rosenthal H, Kubicka S, Krusche S, Merkesdal S, Galanski M, Manns MP, Bleck JS. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. World J Gastroenterol 2006; 12(23): 3707-3715 [PMID: 16773687 DOI: 10.3748/wjg.v12.i23.3707] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
124 Ryder S. Predicting survival in early hepatocellular carcinoma. Gut 2005;54:328-9. [PMID: 15710977 DOI: 10.1136/gut.2004.052092] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
125 Cabral LKD, Tiribelli C, Sukowati CHC. Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity. Cancers (Basel) 2020;12:E1576. [PMID: 32549224 DOI: 10.3390/cancers12061576] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
126 Nojiri S, Kusakabe A, Fujiwara K, Shinkai N, Matsuura K, Iio E, Miyaki T, Nomura T, Sobue S, Sano H, Hasegawa I, Ohno T, Takahashi Y, Orito E, Joh T. Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma. Cancer Manag Res 2012;4:423-9. [PMID: 23293537 DOI: 10.2147/CMAR.S38684] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
127 Boatta E, Corona M, Cannavale A, Fanelli F, Cirelli C, de Medici L. Endovascular treatment of hepatocellular carcinoma with drug eluting microparticles (DC-Beads): CT evaluation of response to the treatment. Indian J Radiol Imaging 2013;23:126-33. [PMID: 24082476 DOI: 10.4103/0971-3026.116564] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
128 Marrero J, Maluccio MA, McCurdy H, Abou-Alfa GK. Expert perspectives on evidence-based treatment planning for patients with hepatocellular carcinoma. Cancer Control 2014;21:5-16. [PMID: 24681845 DOI: 10.1177/1073274814021002s02] [Reference Citation Analysis]
129 Lee KH, Liapi E, Ventura VP, Buijs M, Vossen JA, Vali M, Geschwind JF. Evaluation of different calibrated spherical polyvinyl alcohol microspheres in transcatheter arterial chemoembolization: VX2 tumor model in rabbit liver. J Vasc Interv Radiol. 2008;19:1065-1069. [PMID: 18589321 DOI: 10.1016/j.jvir.2008.02.023] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
130 Bucalau AM, Tancredi I, Verset G. In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play? Cancers (Basel) 2021;13:5129. [PMID: 34680278 DOI: 10.3390/cancers13205129] [Reference Citation Analysis]
131 Wang C, Lu Y, Wang H, Gao X, Bai W, Qu J, Xu G, Zhang Z, Zeng Z, Zhou L, An L, Lv J, Yang Y. Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med 2012;4:188-96. [PMID: 23139708 DOI: 10.3892/etm.2012.569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
132 Williams AA, Archer KJ. Elastic Net Constrained Stereotype Logit Model for Ordered Categorical Data. Biom Biostat Int J 2015;2:00049. [PMID: 30058001 DOI: 10.15406/bbij.2015.02.00049] [Reference Citation Analysis]
133 Pitton MB, Kloeckner R, Ruckes C, Wirth GM, Eichhorn W, Wörns MA, Weinmann A, Schreckenberger M, Galle PR, Otto G, Dueber C. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2015;38:352-60. [PMID: 25373796 DOI: 10.1007/s00270-014-1012-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 6.5] [Reference Citation Analysis]
134 Liu Z, Peng Q, Li Y, Gao Y. Resveratrol enhances cisplatin-induced apoptosis in human hepatoma cells via glutamine metabolism inhibition. BMB Rep 2018;51:474-9. [PMID: 30103844 [PMID: 30103844 DOI: 10.5483/bmbrep.2018.51.9.114] [Cited by in Crossref: 14] [Article Influence: 3.5] [Reference Citation Analysis]
135 Yuan Z, Li WT, Ye XD, Peng WJ, Xiao XS. Utility of diffusion-weighted imaging to assess hepatocellular carcinoma viability following transarterial chemoembolization. Oncol Lett. 2014;8:831-836. [PMID: 25013505 DOI: 10.3892/ol.2014.2228] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
136 Ebeling Barbier C, Heindryckx F, Lennernäs H. Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:13051. [PMID: 34884853 DOI: 10.3390/ijms222313051] [Reference Citation Analysis]
137 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. J Hepatol 2017;67:173-83. [PMID: 28323121 DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 90] [Cited by in F6Publishing: 100] [Article Influence: 18.0] [Reference Citation Analysis]
138 Mazzoccoli G, Tarquini R, Valoriani A, Oben J, Vinciguerra M, Marra F. Management strategies for hepatocellular carcinoma: old certainties and new realities. Clin Exp Med 2016;16:243-56. [PMID: 26077653 DOI: 10.1007/s10238-015-0368-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
139 Schicho A, Hellerbrand C, Krüger K, Beyer LP, Wohlgemuth W, Niessen C, Hohenstein E, Stroszczynski C, Pereira PL, Wiggermann P. Impact of Different Embolic Agents for Transarterial Chemoembolization (TACE) Procedures on Systemic Vascular Endothelial Growth Factor (VEGF) Levels. J Clin Transl Hepatol 2016;4:288-92. [PMID: 28097096 DOI: 10.14218/JCTH.2016.00058] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
140 Kneuertz PJ, Cosgrove DP, Cameron AM, Kamel IR, Geschwind JF, Herman JM, Pawlik TM. Multidisciplinary management of recurrent hepatocellular carcinoma following liver transplantation. J Gastrointest Surg 2012;16:874-81. [PMID: 21975686 DOI: 10.1007/s11605-011-1710-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
141 Cabibbo G, Antonucci M, Genco C. Update on new approaches in the management of hepatocellular carcinoma. Hepat Med 2010;2:163-73. [PMID: 24367214 DOI: 10.2147/HMER.S7132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
142 Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol 2015; 21(42): 12003-12021 [PMID: 26576088 DOI: 10.3748/wjg.v21.i42.12003] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
143 Yang JD, Kim B, Sanderson SO, St Sauver JL, Yawn BP, Pedersen RA, Larson JJ, Therneau TM, Roberts LR, Kim WR. Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008. Mayo Clin Proc 2012;87:9-16. [PMID: 22212963 DOI: 10.1016/j.mayocp.2011.07.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
144 Yang P, Zeng ZC, Wang BL, Zhang JY, Fan J, Zhou J, Hu Y. The Degree of Lipiodol Accumulation Can Be an Indicator of Successful Treatment for Unresectable Hepatocellular Carcinoma (HCC) Patients - in the Case of Transcatheter Arterial Chemoembolization (TACE) and External Beam Radiotherapy (EBRT). J Cancer 2016;7:1413-20. [PMID: 27471557 DOI: 10.7150/jca.15405] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
145 Wang X, Liao X, Yu T, Gong Y, Zhang L, Huang J, Yang C, Han C, Yu L, Zhu G, Qin W, Liu Z, Zhou X, Liu J, Han Q, Peng T. Analysis of clinical significance and prospective molecular mechanism of main elements of the JAK/STAT pathway in hepatocellular carcinoma. Int J Oncol 2019;55:805-22. [PMID: 31485610 DOI: 10.3892/ijo.2019.4862] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
146 Hulin A, Stocco J, Bouattour M. Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. Clin Pharmacokinet 2019;58:983-1014. [PMID: 31093928 DOI: 10.1007/s40262-019-00740-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
147 Ding XX, Zhu QG, Zhang SM, Guan L, Li T, Zhang L, Wang SY, Ren WL, Chen XM, Zhao J, Lin S, Liu ZZ, Bai YX, He B, Zhang HQ. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget. 2017;8:55715-55730. [PMID: 28903454 DOI: 10.18632/oncotarget.18382] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]
148 Kasuya G, Kato H, Yasuda S, Tsuji H, Yamada S, Haruyama Y, Kobashi G, Ebner DK, Okada NN, Makishima H, Miyazaki M, Kamada T, Tsujii H; Liver Cancer Working Group. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials. Cancer 2017;123:3955-65. [PMID: 28662297 DOI: 10.1002/cncr.30816] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 7.2] [Reference Citation Analysis]
149 Cho HS, Seo JW, Kang Y, Bae EJ, Kim HJ, Chang SH, Park DJ. Incidence and risk factors for radiocontrast-induced nephropathy in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization. Clin Exp Nephrol. 2011;15:714-719. [PMID: 21695415 DOI: 10.1007/s10157-011-0470-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
150 Chekunov DA, Polyakov RS, Bagment NN, Moysyuk YG, Fedorov DN, Skipenko OG. [Transarterial therapy for hepatocellular cancer]. Khirurgiia (Mosk) 2015;:43-9. [PMID: 26762077 DOI: 10.17116/hirurgia2015943-49] [Reference Citation Analysis]
151 Ulahannan SV, Duffy AG, McNeel TS, Kish JK, Dickie LA, Rahma OE, McGlynn KA, Greten TF, Altekruse SF. Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology. 2014;60:1637-1644. [PMID: 24996116 DOI: 10.1002/hep.27288] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 7.4] [Reference Citation Analysis]
152 Song DS, Choi JY, Yoo SH, Kim HY, Song MJ, Bae SH, Yoon SK, Chun HJ, Choi BG, Lee HG. DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarteral Chemoembolization: A Pilot Study. Gut Liver 2013;7:89-95. [PMID: 23424047 DOI: 10.5009/gnl.2013.7.1.89] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
153 Kalra N, Gupta P, Chawla Y, Khandelwal N. Locoregional treatment for hepatocellular carcinoma: The best is yet to come. World J Radiol 2015; 7(10): 306-318 [PMID: 26516427 DOI: 10.4329/wjr.v7.i10.306] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
154 Georgiades C. Chemoembolization for Lung Neoplasms: Exuberant Expectations versus Meticulous Investigation. Radiology 2021;301:485-6. [PMID: 34463557 DOI: 10.1148/radiol.2021211488] [Reference Citation Analysis]
155 Gerard B, Bleiberg H. Treatment of hepatocarcinoma. Curr Oncol Rep 2004;6:184-91. [PMID: 15066229 DOI: 10.1007/s11912-004-0048-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
156 Kim TH, Park JW, Kim YJ, Kim BH, Woo SM, Moon SH, Kim SS, Lee WJ, Kim DY, Kim CM. Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma. Strahlenther Onkol 2014;190:882-90. [PMID: 24638270 DOI: 10.1007/s00066-014-0643-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
157 Kishore S, Friedman T, Madoff DC. Update on Embolization Therapies for Hepatocellular Carcinoma. Curr Oncol Rep 2017;19:40. [PMID: 28421483 DOI: 10.1007/s11912-017-0597-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
158 Shpanskaya K, Lungren MP, Tulin-Silver S. Pediatric Interventional Oncology: Endovascular, Percutaneous, and Palliative Procedures. Semin Roentgenol 2019;54:359-66. [PMID: 31706369 DOI: 10.1053/j.ro.2019.06.008] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
159 Yoo SH, Kwon JH, Nam SW, Lee JY, Kim YW, Shim DJ, Lee SW, Jang JW. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin. Cancer Control 2020;27:1073274820935843. [PMID: 32583687 DOI: 10.1177/1073274820935843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Lee JS, Chon YE, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kang W, Choi MS, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Kim HY, Kim TH, Yoo K, Ha Y, Kim MN, Lee JH, Hwang SG, Kim SS, Cho HJ, Cheong JY, Cho SW, Park SH, Heo NY, Hong YM, Yoon KT, Cho M, Park JG, Kang MK, Park SY, Kweon YO, Tak WY, Jang SY, Sinn DH, Kim SU; Korean TACE Study Group. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. Yonsei Med J 2021;62:12-20. [PMID: 33381930 DOI: 10.3349/ymj.2021.62.1.12] [Reference Citation Analysis]
161 Young S, Sanghvi T, Lake JJ, Rubin N, Golzarian J. Predicting post-transarterial chemoembolization outcomes: A comparison of direct and total bilirubin serums levels. Diagn Interv Imaging 2020;101:355-64. [PMID: 31948887 DOI: 10.1016/j.diii.2019.12.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
162 Lungren MP, Towbin AJ, Roebuck DJ, Monroe EJ, Gill AE, Thakor A, Towbin RB, Cahill AM, Matthew Hawkins C. Role of interventional radiology in managing pediatric liver tumors : Part 1: Endovascular interventions. Pediatr Radiol. 2018;48:555-564. [PMID: 29362840 DOI: 10.1007/s00247-018-4068-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
163 Wagle P, Narkhede R, Desai G, Pande P, Kulkarni DR, Varty P. SURGICAL MANAGEMENT OF LARGE HEPATOCELLULAR CARCINOMA: THE FIRST SINGLE-CENTER STUDY FROM WESTERN INDIA. Arq Bras Cir Dig 2020;33:e1505. [PMID: 33237158 DOI: 10.1590/0102-672020190001e1505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
164 Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19. [PMID: 22904613 DOI: 10.2147/BTT.S23907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 27] [Article Influence: 0.5] [Reference Citation Analysis]
165 Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer. 2010;116:1305-1314. [PMID: 20066715 DOI: 10.1002/cncr.24884] [Cited by in Crossref: 120] [Cited by in F6Publishing: 116] [Article Influence: 10.0] [Reference Citation Analysis]
166 Dai QS, Gu HL, Ye S, Zhang YJ, Lin XJ, Lau WY, Peng ZW, Chen MS. Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study. Mol Clin Oncol. 2014;2:1047-1054. [PMID: 25279196 DOI: 10.3892/mco.2014.391] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
167 Zhou Q, Zhou XQ, Zhang T. Reactivation of hepatitis B virus after transarterial chemoembolization and therapeutic effect of antiviral drugs. Shijie Huaren Xiaohua Zazhi 2019; 27(10): 651-655 [DOI: 10.11569/wcjd.v27.i10.651] [Reference Citation Analysis]
168 Kim DY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Shin SW, Choo SW, Do YS, Rhee JC. Milan criteria are useful predictors for favorable outcomes in hepatocellular carcinoma patients undergoing liver transplantation after transarterial chemoembolization. World J Gastroenterol 2006; 12(43): 6992-6997 [PMID: 17109521 DOI: 10.3748/wjg.v12.i43.6992] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
169 Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R. Transarterial approaches to primary and secondary hepatic malignancies. Nat Rev Clin Oncol 2015;12:481-9. [PMID: 25985939 DOI: 10.1038/nrclinonc.2015.78] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
170 Wu L, Yang YF, Ge NJ, Shen SQ, Liang J, Wang Y, Zhou WP, Shen F, Wu MC. Hepatic artery injection of ¹³¹I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study. Eur J Nucl Med Mol Imaging. 2012;39:1306-1315. [PMID: 22588627 DOI: 10.1007/s00259-012-2145-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
171 Guan YS, Liu Y, Zhou XP, Li X, He Q, Sun L. p53 gene (Gendicine) and embolisation overcame recurrent hepatocellular carcinoma. Gut 2005;54:1318-9. [PMID: 15879012 DOI: 10.1136/gut.2005.069237] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
172 Kyrochristos ID, Glantzounis GK, Ziogas DE, Gizas I, Schizas D, Lykoudis EG, Felekouras E, Machairas A, Katsios C, Liakakos T, Cho WC, Roukos DH. From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. Int J Mol Sci 2017;18:E180. [PMID: 28106782 DOI: 10.3390/ijms18010180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
173 Yang T, Tan T, Yang J, Pan J, Hu C, Li J, Xu T, Zou Y. Ruptured hepatoblastoma successfully treated with cisplatin monochemotherapy: A case report. Mol Clin Oncol 2018;9:223-5. [PMID: 30101027 DOI: 10.3892/mco.2018.1643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
174 Mojtahedi A, Yang X, Goswami GK. Embolotherapy in the management of hepatocellular carcinoma. Semin Intervent Radiol 2008;25:234-41. [PMID: 21326513 DOI: 10.1055/s-0028-1085922] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
175 Mancuso A. Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol 2013; 5(6): 302-310 [PMID: 23805354 DOI: 10.4254/wjh.v5.i6.302] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
176 Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, Breatta AD, Gandini G, Nani R, Gasparini D, Cucchetti A, Bolondi L, Trevisani F, PRECISION ITALIA STUDY GROUP. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255-264. [PMID: 24937669 DOI: 10.1038/bjc.2014.199] [Cited by in Crossref: 264] [Cited by in F6Publishing: 235] [Article Influence: 33.0] [Reference Citation Analysis]
177 Minami Y, Yagyu Y, Murakami T, Kudo M. Tracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using Three-Dimensional Cone-Beam CT Angiography. Liver Cancer. 2014;3:53-61. [PMID: 24804177 DOI: 10.1159/000343858] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
178 Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003;52 Suppl 3:iii1-iii8. [PMID: 12692148 DOI: 10.1136/gut.52.suppl_3.iii1] [Cited by in Crossref: 132] [Cited by in F6Publishing: 176] [Article Influence: 6.9] [Reference Citation Analysis]
179 Toyama T, Nitta N, Ohta S, Tanaka T, Nagatani Y, Takahashi M, Murata K, Shiomi H, Naka S, Kurumi Y, Tani T, Tabata Y. Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma. Jpn J Radiol 2012;30:62-8. [PMID: 22194039 DOI: 10.1007/s11604-011-0010-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
180 Yu HP, Xie JM, Li B, Sun YH, Gao QG, Ding ZH, Wu HR, Qin ZH. TIGAR regulates DNA damage and repair through pentosephosphate pathway and Cdk5-ATM pathway. Sci Rep 2015;5:9853. [PMID: 25928429 DOI: 10.1038/srep09853] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
181 Park SE, Cho SB, Baek HJ, Moon JI, Ryu KH, Ha JY, Lee S, Won J, Ahn JH, Kim R, Choi SY. Clinical experience with distal transradial access for endovascular treatment of various noncoronary interventions in a multicenter study. PLoS One 2020;15:e0237798. [PMID: 32822396 DOI: 10.1371/journal.pone.0237798] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
182 Jin B, Wang D, Lewandowski RJ, Ryu RK, Sato KT, Larson AC, Salem R, Omary RA. Quantitative 4D transcatheter intraarterial perfusion MRI for standardizing angiographic chemoembolization endpoints. AJR Am J Roentgenol 2011;197:1237-43. [PMID: 22021520 DOI: 10.2214/AJR.10.5821] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
183 Salem R, Lewandowski RJ. Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11:604-11; quiz e43-44. [PMID: 23357493 DOI: 10.1016/j.cgh.2012.12.039] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
184 Jang JH, Lee JW, Hong JT, Jin YJ. Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy. J Hepatocell Carcinoma 2015;2:123-9. [PMID: 27508201 DOI: 10.2147/JHC.S44380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
185 Yang K, Zhang XM, Yang L, Xu H, Peng J. Advanced imaging techniques in the therapeutic response of transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2016;22:4835-47. [PMID: 27239110 DOI: 10.3748/wjg.v22.i20.4835] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
186 Schütte K, Schulz C, Malfertheiner P. Hepatocellular Carcinoma: Current Concepts in Diagnosis, Staging and Treatment. Gastrointest Tumors 2014;1:84-92. [PMID: 26672483 DOI: 10.1159/000362583] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
187 Feng JK, Sun JX, Liu ZH, Gu JW, Chen ZH, Liu C, Guo WX, Shi J, Cheng SQ. Efficacy and Safety of Transarterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma Associated with Bile Duct Tumor Thrombus: A Real-World Retrospective Cohort Study. Cancer Manag Res 2021;13:3551-60. [PMID: 33953609 DOI: 10.2147/CMAR.S307065] [Reference Citation Analysis]
188 Raza A, Sood GK. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J Gastroenterol 2014; 20(15): 4115-4127 [PMID: 24764650 DOI: 10.3748/wjg.v20.i15.4115] [Cited by in CrossRef: 237] [Cited by in F6Publishing: 220] [Article Influence: 29.6] [Reference Citation Analysis]
189 Wang D, Virmani S, Tang R, Szolc-Kowalska B, Woloschak G, Omary RA, Larson AC. Four-dimensional transcatheter intraarterial perfusion (TRIP)-MRI for monitoring liver tumor embolization in VX2 rabbits. Magn Reson Med 2008;60:970-5. [PMID: 18816818 DOI: 10.1002/mrm.21678] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
190 Nagaoka S, Itano S, Nagamatsu H, Akiyoshi J, Kurogi J, Tajiri N, Kajiwara M, Sata M. Temporary indwelling catheter system via the left brachial artery: evaluation in 83 patients with hepatic tumors. AJR Am J Roentgenol 2007;188:652-8. [PMID: 17312050 DOI: 10.2214/AJR.05.0693] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
191 Ogawa K, Kamimura K, Watanabe Y, Motai Y, Kumaki D, Seki R, Sakamaki A, Abe S, Kawai H, Suda T, Yamagiwa S, Terai S. Effect of double platinum agents, combination of miriplatin-transarterial oily chemoembolization and cisplatin-hepatic arterial infusion chemotherapy, in patients with hepatocellular carcinoma: Report of two cases. World J Clin Cases 2017; 5(6): 238-246 [PMID: 28685137 DOI: 10.12998/wjcc.v5.i6.238] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
192 Liu P, Lee Y, Hsu C, Hsia C, Huang Y, Chiou Y, Lin H, Huo T. Surgical Resection Is Better than Transarterial Chemoembolization for Hepatocellular Carcinoma Beyond Milan Criteria Independent of Performance Status. J Gastrointest Surg 2014;18:1623-31. [DOI: 10.1007/s11605-014-2546-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
193 Vogl TJ, Naguib NN, Nour-Eldin NE, Eichler K, Zangos S, Gruber-Rouh T. Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. Eur Radiol. 2010;20:173-180. [PMID: 19657653 DOI: 10.1007/s00330-009-1525-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
194 Huang M, Wang L, Chen J, Bai M, Zhou C, Liu S, Lin Q. Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1α is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery. Int J Oncol 2016;48:2144-54. [PMID: 26984380 DOI: 10.3892/ijo.2016.3421] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
195 Parvinian A, Casadaban LC, Hauck ZZ, van Breemen RB, Gaba RC. Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model. Diagn Interv Radiol 2015;21:235-40. [PMID: 25835078 DOI: 10.5152/dir.2014.14394] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
196 He M, Li Q, Shen J, Tan G, Li Q, Lai J, Wei W, Zhang Y, Zou R, Chen M, Guo R, Shi M. Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. Cancer Med 2019;8:4200-13. [PMID: 31207163 DOI: 10.1002/cam4.2355] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
197 Whisenant J, Venook A. Regional therapy of liver metastases. Curr Treat Options Oncol 2004;5:427-37. [PMID: 15341680 DOI: 10.1007/s11864-004-0032-4] [Reference Citation Analysis]
198 Kuo YC, Kohi MP, Naeger DM, Tong RT, Kolli KP, Taylor AG, Laberge JM, Kerlan RK, Fidelman N. Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol. 2013;36:1336-1343. [PMID: 23864021 DOI: 10.1007/s00270-013-0698-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
199 Hass P, Mohnike K. Extending the Frontiers Beyond Thermal Ablation by Radiofrequency Ablation: SBRT, Brachytherapy, SIRT (Radioembolization). Viszeralmedizin 2014;30:245-52. [PMID: 26288597 DOI: 10.1159/000366088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
200 Ramanathan R, Sharma A, Lee DD, Behnke M, Bornstein K, Stravitz RT, Sydnor M, Fulcher A, Cotterell A, Posner MP. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. Transplantation. 2014;98:100-106. [PMID: 24503764 DOI: 10.1097/01.tp.0000441090.39840.b0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
201 Kim KM. Nonsurgical multidisciplinary approach for recurrent hepatocellular carcinoma after surgical resection. Hepat Oncol 2015;2:29-38. [PMID: 30190985 DOI: 10.2217/hep.14.31] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
202 Maeda N, Osuga K, Mikami K, Higashihara H, Onishi H, Nakaya Y, Tatsumi M, Hori M, Kim T, Tomoda K, Nakamura H. Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma. Radiat Med 2008;26:206-12. [DOI: 10.1007/s11604-007-0216-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
203 Lee S, Kim H, Ji Y, Cho B, Kim SS, Jung J, Kwak J, Park JH, Lee SW, Kim JH, Yoon SM. Evaluation of Hepatic Toxicity after Repeated Stereotactic Body Radiation Therapy for Recurrent Hepatocellular Carcinoma using Deformable Image Registration. Sci Rep 2018;8:16224. [PMID: 30385839 DOI: 10.1038/s41598-018-34676-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
204 Trevisani F, Giannini EG; Italian Liver Cancer (ITA.LI.CA) group. The ITA.LI.CA Consortium: How multicentre collaboration helped shape the management of patients with hepatocellular carcinoma on the basis of real-world evidence. Ann Hepatol 2021;:100564. [PMID: 34688886 DOI: 10.1016/j.aohep.2021.100564] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
205 Yousef S, Alsaab HO, Sau S, Iyer AK. Development of asialoglycoprotein receptor directed nanoparticles for selective delivery of curcumin derivative to hepatocellular carcinoma. Heliyon 2018;4:e01071. [PMID: 30603704 DOI: 10.1016/j.heliyon.2018.e01071] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
206 Chai NX, Chapiro J. Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice. Semin Intervent Radiol 2020;37:456-65. [PMID: 33328701 DOI: 10.1055/s-0040-1719186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
207 Kong JY, Li SM, Fan HY, Zhang L, Zhao HJ, Li SM. Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e11872. [PMID: 30113483 DOI: 10.1097/MD.0000000000011872] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
208 Chen B, Garmire L, Calvisi DF, Chua MS, Kelley RK, Chen X. Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020;17:238-51. [PMID: 31900465 DOI: 10.1038/s41575-019-0240-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
209 Seki A, Hori S, Shimono C. Management of vascular lake phenomenon on angiography during chemoembolization with superabsorbent polymer microspheres. Jpn J Radiol. 2015;33:741-748. [PMID: 26493810 DOI: 10.1007/s11604-015-0486-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
210 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015;7:738-52. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Reference Citation Analysis]
211 Yang DS, Park S, Rim CH, Yoon WS, Shin IS, Lee HA. Salvage External Beam Radiotherapy after Incomplete Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review. Medicina (Kaunas) 2021;57:1000. [PMID: 34684036 DOI: 10.3390/medicina57101000] [Reference Citation Analysis]
212 Lucatelli P, Burrel M, Guiu B, de Rubeis G, van Delden O, Helmberger T. CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. Cardiovasc Intervent Radiol 2021;44:1851-67. [PMID: 34694454 DOI: 10.1007/s00270-021-02968-1] [Reference Citation Analysis]
213 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 310] [Article Influence: 28.2] [Reference Citation Analysis]
214 Wu FX, Chen J, Bai T, Zhu SL, Yang TB, Qi LN, Zou L, Li ZH, Ye JZ, Li LQ. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. BMC Cancer 2017;17:645. [PMID: 28899349 DOI: 10.1186/s12885-017-3545-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
215 Qu S, Zhang X, Wu Y, Meng Y, Pan H, Fang Q, Hu L, Zhang J, Wang R, Wei L, Wu D. Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study. Front Oncol 2022;12:874473. [DOI: 10.3389/fonc.2022.874473] [Reference Citation Analysis]
216 Yi PS, Zhang M, Zhao JT, Xu MQ. Liver resection for intermediate hepatocellular carcinoma. World J Hepatol 2016; 8(14): 607-615 [PMID: 27190577 DOI: 10.4254/wjh.v8.i14.607] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
217 Vosshenrich J, Zech CJ, Heye T, Boldanova T, Fucile G, Wieland S, Heim MH, Boll DT. Response prediction of hepatocellular carcinoma undergoing transcatheter arterial chemoembolization: unlocking the potential of CT texture analysis through nested decision tree models. Eur Radiol 2021;31:4367-76. [PMID: 33274405 DOI: 10.1007/s00330-020-07511-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
218 Yang L, Zhang XM, Zhou XP, Tang W, Guan YS, Zhai ZH, Dong GL. Correlation between tumor perfusion and lipiodol deposition in hepatocellular carcinoma after transarterial chemoembolization. J Vasc Interv Radiol 2010;21:1841-6. [PMID: 20980165 DOI: 10.1016/j.jvir.2010.08.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
219 White JA, Redden DT, Bryant MK, Dorn D, Saddekni S, Abdel Aal AK, Zarzour J, Bolus D, Smith JK, Gray S, Eckhoff DE, DuBay DA. Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma. HPB (Oxford) 2014;16:1095-101. [PMID: 25158123 DOI: 10.1111/hpb.12313] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
220 Lin CT, Hsu KF, Chen TW, Yu JC, Chan DC, Yu CY, Hsieh TY, Fan HL, Kuo SM, Chung KP, Hsieh CB. Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice? World J Surg. 2010;34:2155-2161. [PMID: 20407768 DOI: 10.1007/s00268-010-0598-x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 5.0] [Reference Citation Analysis]
221 Ogasawara S, Kanai F, Obi S, Sato S, Yamaguchi T, Azemoto R, Mizumoto H, Koushima Y, Morimoto N, Hirata N. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int. 2011;5:850-856. [PMID: 21484134 DOI: 10.1007/s12072-010-9249-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
222 Kis B, El-Haddad G, Sheth RA, Parikh NS, Ganguli S, Shyn PB, Choi J, Brown KT. Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control 2017;24:1073274817729244. [PMID: 28975829 DOI: 10.1177/1073274817729244] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
223 Liang B, Xiong F, Wu H, Wang Y, Dong X, Cheng S, Feng G, Zhou G, Xiong B, Liang H, Xia X, Zheng C. Effect of transcatheter intraarterial therapies on the distribution of Doxorubicin in liver cancer in a rabbit model. PLoS One 2013;8:e76388. [PMID: 24116106 DOI: 10.1371/journal.pone.0076388] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
224 Collettini F, Schnapauff D, Poellinger A, Denecke T, Schott E, Berg T, Wust P, Hamm B, Gebauer B. Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5-7 cm) and very large (>7 cm) tumours. Eur Radiol 2012;22:1101-9. [PMID: 22173693 DOI: 10.1007/s00330-011-2352-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
225 Leal JN, Gonen M, Covey AM, Erinjeri JP, Getrajdman G, Sofocleous CT, D'Angelica M, DeMatteo RP, Abou-Alfa GK, Jarnagin WR, Fong Y, Brown KT. Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread. J Vasc Interv Radiol 2015;26:1112-21. [PMID: 26038273 DOI: 10.1016/j.jvir.2015.04.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
226 Solbach P, Potthoff A, Raatschen HJ, Soudah B, Lehmann U, Schneider A, Gebel MJ, Manns MP, Vogel A. Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report. BMC Gastroenterol 2015;15:60. [PMID: 25986067 DOI: 10.1186/s12876-015-0288-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
227 Meyers BM, Knox J, Cosby R, Beecroft JR, Chan KKW, Coburn N, Feld J, Jonker D, Mahmud A, Ringash J; Gastrointestinal Disease Site Group. Nonsurgical management of advanced hepatocellular carcinoma: a clinical practice guideline. Curr Oncol 2020;27:e106-14. [PMID: 32489260 DOI: 10.3747/co.27.5891] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
228 Bae SI, Yeon JE, Lee JM, Kim JH, Lee HJ, Lee SJ, Suh SJ, Yoon EL, Kim HR, Byun KS, Seo TS. A case of necrotizing pancreatitis subsequent to transcatheter arterial chemoembolization in a patient with hepatocellular carcinoma. Clin Mol Hepatol 2012;18:321-5. [PMID: 23091814 DOI: 10.3350/cmh.2012.18.3.321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
229 Ishikawa T. Strategy for improving survival and reducing recurrence of HCV-related hepatocellular carcinoma. World J Gastroenterol 2013; 19(37): 6127-6130 [PMID: 24115808 DOI: 10.3748/wjg.v19.i37.6127] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
230 Yang S, Lin H, Song J. Efficacy and safety of various primary treatment strategies for very early and early hepatocellular carcinoma: a network meta-analysis. Cancer Cell Int 2021;21:681. [PMID: 34923980 DOI: 10.1186/s12935-021-02365-1] [Reference Citation Analysis]
231 Fang ZT, Wang GZ, Zhang W, Qu XD, Liu R, Qian S, Zhu L, Zhou B, Wang JH. Transcatheter arterial embolization promotes liver tumor metastasis by increasing the population of circulating tumor cells. Onco Targets Ther 2013;6:1563-72. [PMID: 24235842 DOI: 10.2147/OTT.S52973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
232 Choi TW, Kim HC, Lee JH, Yu SJ, Kang B, Hur S, Lee M, Jae HJ, Chung JW. The Safety and Clinical Outcomes of Chemoembolization in Child-Pugh Class C Patients with Hepatocellular Carcinomas. Korean J Radiol. 2015;16:1283-1293. [PMID: 26576118 DOI: 10.3348/kjr.2015.16.6.1283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
233 Toshima T, Taketomi A, Shirabe K, Takeishi K, Motomura T, Mano Y, Morita K, Fukuhara T, Sugimachi K, Maruoka Y, Abe K, Tajima T, Maehara Y. Solitary Asymptomatic Thyroid Metastasis from Hepatocellular Carcinoma Detected by FDG-PET/CT. Case Rep Gastroenterol 2010;4:279-85. [PMID: 21383951 DOI: 10.1159/000318858] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
234 Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. World J Gastroenterol 2018; 24(2): 161-169 [PMID: 29375202 DOI: 10.3748/wjg.v24.i2.161] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 41] [Article Influence: 12.5] [Reference Citation Analysis]
235 Lee SW, Lee HL, Han NI, Kwon JH, Nam SW, Jang JW, Bae SH, Choi JY, Yoon SK. Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis. Ther Adv Med Oncol 2017;9:615-26. [PMID: 28974984 DOI: 10.1177/1758834017728018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
236 Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17:1226-1233. [PMID: 20405327 DOI: 10.1245/s10434-010-0978-3.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
237 Goumard C, Komatsu S, Brustia R, Fartoux L, Soubrane O, Scatton O. Technical feasibility and safety of laparoscopic right hepatectomy for hepatocellular carcinoma following sequential TACE-PVE: a comparative study. Surg Endosc. 2017;31:2340-2349. [PMID: 27655376 DOI: 10.1007/s00464-016-5225-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
238 Li H, Chen L, Zhu GY, Yao X, Dong R, Guo JH. Interventional Treatment for Cholangiocarcinoma. Front Oncol 2021;11:671327. [PMID: 34268114 DOI: 10.3389/fonc.2021.671327] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
239 Kaseb AO, Shah NN, Hassabo HM, Morris JS, Xiao L, Abaza YM, Soliman K, Lee JS, Vauthey JN, Wallace M. Reassessing hepatocellular carcinoma staging in a changing patient population. Oncology. 2014;86:63-71. [PMID: 24401634 DOI: 10.1159/000356573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
240 Gao J, Zhen R, Liao H, Zhuang W, Guo W. Pharmacokinetics of continuous transarterial infusion of 5-fluorouracil in patients with advanced hepatocellular carcinoma. Oncol Lett. 2018;15:7175-7181. [PMID: 29725440 DOI: 10.3892/ol.2018.8242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
241 Jun CH, Ki HS, Lee KH, Park KJ, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK. Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE. Clin Mol Hepatol. 2013;19:70-77. [PMID: 23593612 DOI: 10.3350/cmh.2013.19.1.70] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
242 Bruera G, Cannita K, Giordano AV, Manetta R, Vicentini R, Carducci S, Saltarelli P, Iapadre N, Coletti G, Ficorella C. Multidisciplinary management of hepatocellular carcinoma in clinical practice. Biomed Res Int. 2014;2014:806391. [PMID: 24900987 DOI: 10.1155/2014/806391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
243 Liu J, Wang D, Zhou J, Wang L, Zhang N, Zhou L, Zeng J, Liu J, Yang M. N6-methyladenosine reader YTHDC2 and eraser FTO may determine hepatocellular carcinoma prognoses after transarterial chemoembolization. Arch Toxicol 2021;95:1621-9. [PMID: 33713148 DOI: 10.1007/s00204-021-03021-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
244 Lee SJ, Cho EH, Kim R, Kim YH, Lim CS, Kim SB. Hepatectomy, combined with intraoperative radiofrequency ablation in patients with multiple hepatocellular carcinomas. Korean J Hepatobiliary Pancreat Surg 2015;19:98-102. [PMID: 26379730 DOI: 10.14701/kjhbps.2015.19.3.98] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
245 Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients. BMC Cancer. 2011;11:202. [PMID: 21615953 DOI: 10.1186/1471-2407-11-202] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
246 Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 2017;66:545-51. [PMID: 27816492 DOI: 10.1016/j.jhep.2016.10.029] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
247 Kim AY, Yacoub JH, Field DH, Park BU, Kallakury B, Korolowicz KE, Menne S. Suitability of the woodchuck HCC as a preclinical model for evaluation of intra-arterial therapies. Animal Model Exp Med. 2020;3:98-102. [PMID: 32318666 DOI: 10.1002/ame2.12100] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
248 Bossé D, Ng T, Ahmad C, Alfakeeh A, Alruzug I, Biagi J, Brierley J, Chaudhury P, Cleary S, Colwell B, Cripps C, Dawson LA, Dorreen M, Ferland E, Galiatsatos P, Girard S, Gray S, Halwani F, Kopek N, Mahmud A, Martel G, Robillard L, Samson B, Seal M, Siddiqui J, Sideris L, Snow S, Thirwell M, Vickers M, Goodwin R, Goel R, Hsu T, Tsvetkova E, Ward B, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Curr Oncol 2016;23:e605-14. [PMID: 28050151 DOI: 10.3747/co.23.3394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
249 Iwazawa J, Ohue S, Hashimoto N, Mitani T. Comparison of the Number of Image Acquisitions and Procedural Time Required for Transarterial Chemoembolization of Hepatocellular Carcinoma with and without Tumor-Feeder Detection Software. Radiol Res Pract 2013;2013:580839. [PMID: 23984066 DOI: 10.1155/2013/580839] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
250 Ingraham C, Johnson G, Padia SA, Vaidya S. Interventional Radiology for Liver Lesions. Semin Roentgenol 2016;51:367-77. [PMID: 27743571 DOI: 10.1053/j.ro.2016.05.017] [Reference Citation Analysis]
251 Liu X, Liao G, Luo X, Song W, Zhang H, Chen H, Cai S, Guo D. Hepatocellular Carcinoma With Different Areas of Right Retroperitoneal Space Invasion: Evaluation of Transcatheter Arterial Chemoembolization Efficacy and Blood Supply Characteristics. Front Oncol 2020;10:539692. [PMID: 33072569 DOI: 10.3389/fonc.2020.539692] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
252 Gross-Goupil M, Saffroy R, Azoulay D, Precetti S, Emile JF, Delvart V, Tindilière F, Laurent A, Bellin MF, Bismuth H. Real-time quantification of AFP mRNA to assess hematogenous dissemination after transarterial chemoembolization of hepatocellular carcinoma. Ann Surg. 2003;238:241-248. [PMID: 12894018 DOI: 10.1097/01.sla.0000080959.95226.be] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 0.6] [Reference Citation Analysis]
253 Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, Maeda H, Matsuo K, Nishida N, Aramaki T, Anai H, Koura S, Oikawa S, Watanabe K, Yasumoto T, Furuichi K, Yamaguchi M. Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization. Jpn J Radiol 2014;32:260-5. [PMID: 24615165 DOI: 10.1007/s11604-014-0298-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
254 Zhong JH, Du XK, Xiang BD, Li LQ. Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial. World J Hepatol 2016; 8(23): 957-960 [PMID: 27621761 DOI: 10.4254/wjh.v8.i23.957] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
255 Li J, Shi C, Shi J, Song J, Wang N. Determination of risk factors for fever after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e27636. [PMID: 34871232 DOI: 10.1097/MD.0000000000027636] [Reference Citation Analysis]
256 Fidelman N, Johanson C, Kohi MP, Kolli KP, Kohlbrenner RM, Lehrman ED, Taylor AG, Kelley RK, Yao FY, Roberts JP, Kerlan RK. Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve. J Hepatocell Carcinoma 2019;6:93-103. [PMID: 31355158 DOI: 10.2147/JHC.S206979] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
257 Hayano K, Fuentes-Orrego JM, Sahani DV. New approaches for precise response evaluation in hepatocellular carcinoma. World J Gastroenterol 2014; 20(12): 3059-3068 [PMID: 24696594 DOI: 10.3748/wjg.v20.i12.3059] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
258 Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, Davies N, Williams E, Pereira SP, Hochhauser D, Mayer A, Gillmore R, O'Beirne J, Patch D, Burroughs AK. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer. 2013;108:1252-1259. [PMID: 23449352 DOI: 10.1038/bjc.2013.85] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 8.9] [Reference Citation Analysis]
259 Poon RT, Cheung TT, Kwok PC, Lee AS, Li TW, Loke KL, Chan SL, Cheung MT, Lai TW, Cheung CC. Hong Kong consensus recommendations on the management of hepatocellular carcinoma. Liver Cancer. 2015;4:51-69. [PMID: 26020029 DOI: 10.1159/000367728] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
260 Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N, Milicevic M. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol 2015; 7(20): 2274-2291 [PMID: 26380652 DOI: 10.4254/wjh.v7.i20.2274] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
261 Chen S, Yu W, Zhang K, Liu W, Chen Q. Transarterial chemoembolization for unresectable hepatocellular carcinoma: A comparison of the efficacy and safety of 2 embolic agents. Medicine (Baltimore) 2018;97:e10832. [PMID: 29794774 DOI: 10.1097/MD.0000000000010832] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
262 Kawamura Y, Ikeda K, Fukushima T, Seko Y, Hara T, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S. What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study. Gut Liver. 2013;7:576-584. [PMID: 24073316 DOI: 10.5009/gnl.2013.7.5.576] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
263 Steiner K, Papadopoulou A, Yu D. The role of interventional radiology in the treatment of hepatocellular carcinoma. Semin Ultrasound CT MR 2013;34:89-101. [PMID: 23395321 DOI: 10.1053/j.sult.2012.11.008] [Reference Citation Analysis]
264 Lee S, Jung J, Park JH, Kim SY, Choi J, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Park HH, Kim JH, Yoon SM. Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients. BMC Cancer 2022;22:175. [PMID: 35172769 DOI: 10.1186/s12885-022-09263-3] [Reference Citation Analysis]
265 Gusani NJ, Balaa FK, Steel JL, Geller DA, Marsh JW, Zajko AB, Carr BI, Gamblin TC. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): A single-institution experience. Journal of Gastrointestinal Surgery. 2008;12:129-137. [PMID: 17851723 DOI: 10.1007/s11605-007-0312-y] [Cited by in Crossref: 87] [Cited by in F6Publishing: 74] [Article Influence: 5.8] [Reference Citation Analysis]
266 Huang BS, Tsang NM, Lin SM, Lin DY, Lien JM, Lin CC, Chen WT, Chen WY, Hong JH. High-dose hypofractionated X-ray radiotherapy for hepatocellular carcinoma: Tumor responses and toxicities. Oncol Lett 2013;6:1514-20. [PMID: 24179551 DOI: 10.3892/ol.2013.1582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
267 Yin X, Zhang L, Wang YH, Zhang BH, Gan YH, Ge NL, Chen Y, Li LX, Ren ZG. Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma. BMC Cancer. 2014;14:849. [PMID: 25409554 DOI: 10.1186/1471-2407-14-849] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
268 Lin J, Wu L, Bai X, Xie Y, Wang A, Zhang H, Yang X, Wan X, Lu X, Sang X, Zhao H. Combination treatment including targeted therapy for advanced hepatocellular carcinoma. Oncotarget 2016;7:71036-51. [PMID: 27626176 DOI: 10.18632/oncotarget.11954] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
269 Lee S, Loecher M, Iyer R. Immunomodulation in hepatocellular cancer. J Gastrointest Oncol. 2018;9:208-219. [PMID: 29564186 DOI: 10.21037/jgo.2017.06.08] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
270 Cho Y, Kim JW, Kim JK, Lee KS, Lee JI, Lee HW, Lee KH, Joo SM, Lim JH, Lee IJ. Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1612. [PMID: 32570869 DOI: 10.3390/cancers12061612] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
271 Baumgarten S, Gaba RC, van Breemen RB. Confirmation of drug delivery after liver chemoembolization: direct tissue doxorubicin measurement by UHPLC-MS-MS. Biomed Chromatogr 2012;26:1529-33. [PMID: 22454282 DOI: 10.1002/bmc.2727] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
272 Nitta-Seko A, Nitta N, Sonoda A, Otani H, Tsuchiya K, Ohta S, Takahashi M, Murata K. Anti-tumour effects of transcatheter arterial embolisation administered in combination with thalidomide in a rabbit VX2 liver tumour model. Br J Radiol 2011;84:179-83. [PMID: 20959369 DOI: 10.1259/bjr/53771502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
273 Roberts HJ, Wo JY. Stereotactic body radiation therapy for primary liver tumors: An effective liver-directed therapy in the toolbox. Cancer 2021. [PMID: 34847255 DOI: 10.1002/cncr.34033] [Reference Citation Analysis]
274 Jiang JM, Ohri N, Tang J, Moadel R, Cynamon J, Kaubisch A, Kinkhabwala M, Garg MK, Guha C, Kabarriti R. Centers with more therapeutic modalities are associated with improved outcomes for patients with hepatocellular carcinoma. J Gastrointest Oncol 2019;10:546-53. [PMID: 31183206 DOI: 10.21037/jgo.2019.01.30] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
275 Lewandowski RJ, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB, Ibrahim SM, Abecassis MI, Miller FH, Sato KT, Senthilnathan S, Resnick SA, Wang E, Gupta R, Chen R, Newman SB, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Omary RA, Benson AB 3rd, Salem R. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010;255:955-65. [PMID: 20501733 DOI: 10.1148/radiol.10091473] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 9.0] [Reference Citation Analysis]
276 Gai X, Zhou P, Xu M, Liu Z, Zheng X, Liu Q. Hyperactivation of IL-6/STAT3 pathway leaded to the poor prognosis of post-TACE HCCs by HIF-1α/SNAI1 axis-induced epithelial to mesenchymal transition. J Cancer 2020;11:570-82. [PMID: 31942180 DOI: 10.7150/jca.35631] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
277 Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408-424. [PMID: 26054909 DOI: 10.1038/nrclinonc.2015.103] [Cited by in Crossref: 260] [Cited by in F6Publishing: 261] [Article Influence: 37.1] [Reference Citation Analysis]
278 Kamimura K, Suda T, Tamura Y, Takamura M, Yokoo T, Igarashi M, Kawai H, Yamagiwa S, Nomoto M, Aoyagi Y. Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma. BMC Gastroenterol 2012;12:127. [PMID: 22994941 DOI: 10.1186/1471-230X-12-127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
279 Yang T, Yang J, Tan T, Pan J, Hu C, Li J, Zou Y. Cure of Hepatoblastoma Through Transcatheter Arterial Chemoembolization. Glob Pediatr Health 2017;4:2333794X17742750. [PMID: 29226184 DOI: 10.1177/2333794X17742750] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
280 Lee S, Yoon SH, Park JY, Kim DY, Ahn SH, Han K, Choi HJ. Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. Invest New Drugs 2012;30:1150-7. [DOI: 10.1007/s10637-011-9634-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
281 Palmer DH, Johnson PJ. Pre-operative locoregional therapy and liver transplantation for hepatocellular carcinoma: time for a randomized controlled trial. Am J Transplant 2005;5:641-2. [PMID: 15760384 DOI: 10.1111/j.1600-6143.2005.00856.x] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
282 Yamanaka K, Hatano E, Kitamura K, Iida T, Ishii T, Machimito T, Taura K, Yasuchika K, Isoda H, Shibata T. Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma. J Gastroenterol. 2012;47:343-346. [PMID: 22183859 DOI: 10.1007/s00535-011-0511-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
283 Dorcaratto D, Udupa V, Hogan NM, Brophy DP, McCann JW, Maguire D, Geoghegan J, Cantwell CP, Hoti E. Does neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization improve survival in patients undergoing liver transplant for hepatocellular carcinoma? Diagn Interv Radiol 2017;23:441-7. [PMID: 29063856 DOI: 10.5152/dir.2017.17106] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
284 Liu BJ, Gao S, Zhu X, Guo JH, Zhang X, Chen H, Wang XD, Yang RJ. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(6): 663-676 [PMID: 32699581 DOI: 10.4251/wjgo.v12.i6.663] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
285 Lin P, Teng W, Jeng W, Chen W, Hsieh Y, Huang C, Lui K, Hung C, Wang C, Chai P, Lin C, Lin C, Lin S, Sheen I. Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization. Diagnostics 2022;12:665. [DOI: 10.3390/diagnostics12030665] [Reference Citation Analysis]
286 Li H, Li S, Geng J, Zhao S, Tan K, Yang Z, Feng D, Liu L. Efficacy evaluation of the combination therapy of sorafenib and transarterial chemoembolization for unresectable HCC: a systematic review and meta-analysis of comparative studies. Ann Transl Med 2020;8:540. [PMID: 32411763 DOI: 10.21037/atm.2020.02.115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
287 Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30:6-25. [PMID: 17103105 DOI: 10.1007/s00270-006-0062-3] [Cited by in Crossref: 564] [Cited by in F6Publishing: 526] [Article Influence: 37.6] [Reference Citation Analysis]
288 Kim YW, Kwon JH, Nam SW, Jang JW, Jung HS, Shin YR, Park ES, Shim DJ. Sustained multiple organ ischaemia after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. Exp Ther Med 2018;15:1479-83. [PMID: 29434732 DOI: 10.3892/etm.2017.5540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
289 Shah KY, Gaba RC. Combined Transarterial Chemoembolization and Percutaneous Radiofrequency Ablation: More Promising Evidence of Effectiveness in Treating Solitary, Medium-Sized Hepatocellular Carcinoma. J Vasc Interv Radiol 2019;30:1545-8. [PMID: 31547921 DOI: 10.1016/j.jvir.2019.07.005] [Reference Citation Analysis]
290 Aladdin M, Ilyas M. Chemoembolization of hepatocellular carcinoma with drug-eluting beads complicated by interstitial pneumonitis. Semin Intervent Radiol. 2011;28:218-221. [PMID: 22654266 DOI: 10.1055/s-0031-1280668] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
291 Liu C, Wu H, Mao Y, Chen W, Chen S. Exosomal microRNAs in hepatocellular carcinoma. Cancer Cell Int 2021;21:254. [PMID: 33964930 DOI: 10.1186/s12935-021-01941-9] [Reference Citation Analysis]
292 Ng J, Wu J. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon 2012;12:e7635. [PMID: 23233865 DOI: 10.5812/hepatmon.7635] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
293 Paik EK, Kim MS, Jang WI, Seo YS, Cho CK, Yoo HJ, Han CJ, Park SC, Kim SB, Kim YH. Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma. Radiat Oncol. 2016;11:22. [PMID: 26896371 DOI: 10.1186/s13014-016-0597-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
294 Moreno-Luna LE, Yang JD, Sanchez W, Paz-Fumagalli R, Harnois DM, Mettler TA, Gansen DN, de Groen PC, Lazaridis KN, Narayanan Menon KV, Larusso NF, Alberts SR, Gores GJ, Fleming CJ, Slettedahl SW, Harmsen WS, Therneau TM, Wiseman GA, Andrews JC, Roberts LR. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2013;36:714-723. [PMID: 23093355 DOI: 10.1007/s00270-012-0481-2] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 8.2] [Reference Citation Analysis]
295 Taura K, Ikai I, Hatano E, Fujii H, Uyama N, Shimahara Y. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. Ann Surg. 2006;244:265-273. [PMID: 16858190 DOI: 10.1097/01.sla.0000217921.28563.55] [Cited by in Crossref: 98] [Cited by in F6Publishing: 83] [Article Influence: 6.1] [Reference Citation Analysis]
296 Titano J, Noor A, Kim E. Transarterial Chemoembolization and Radioembolization across Barcelona Clinic Liver Cancer Stages. Semin Intervent Radiol 2017;34:109-15. [PMID: 28579678 DOI: 10.1055/s-0037-1602709] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
297 Hou Z, Liu J, Jin Z, Qiu G, Xie Q, Mi S, Huang J. Use of chemotherapy to treat hepatocellular carcinoma. Biosci Trends 2022. [PMID: 35173139 DOI: 10.5582/bst.2022.01044] [Reference Citation Analysis]
298 Qian J, Oppermann E, Tran A, Imlau U, Qian K, Vogl TJ. Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model. World J Gastroenterol 2016; 22(21): 5042-5049 [PMID: 27275096 DOI: 10.3748/wjg.v22.i21.5042] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
299 Zhou C, Shi Q, Liu J, Huang S, Yang C, Xiong B. Effect of Inhibiting Tumor Angiogenesis After Embolization in the Treatment of HCC with Apatinib-Loaded p(N-Isopropyl-Acrylamide-co-Butyl Methyl Acrylate) Temperature-Sensitive Nanogel. J Hepatocell Carcinoma 2020;7:447-56. [PMID: 33409168 DOI: 10.2147/JHC.S282209] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
300 Miyayama S. Ultraselective conventional transarterial chemoembolization: When and how? Clin Mol Hepatol 2019;25:344-53. [PMID: 31022779 DOI: 10.3350/cmh.2019.0016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
301 Krieg S, Essing T, Krieg A, Roderburg C, Luedde T, Loosen SH. Recent Trends and In-Hospital Mortality of Transarterial Chemoembolization (TACE) in Germany: A Systematic Analysis of Hospital Discharge Data between 2010 and 2019. Cancers 2022;14:2088. [DOI: 10.3390/cancers14092088] [Reference Citation Analysis]
302 Burak KW, Kneteman NM. An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. Can J Gastroenterol 2010;24:643-50. [PMID: 21157578 DOI: 10.1155/2010/410574] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
303 Rai V, Mukherjee S. Targets of immunotherapy for hepatocellular carcinoma: An update. World J Hepatol 2022; 14(1): 140-157 [DOI: 10.4254/wjh.v14.i1.140] [Reference Citation Analysis]
304 Chen ZX, Jian ZW, Wu XW, Wang JC, Peng JY, Lao XM. Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization. Cancer Med 2019;8:5097-107. [PMID: 31313476 DOI: 10.1002/cam4.2380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
305 Ziv E, Yarmohammadi H, Boas FE, Petre EN, Brown KT, Solomon SB, Solit D, Reidy D, Erinjeri JP. Gene Signature Associated with Upregulation of the Wnt/β-Catenin Signaling Pathway Predicts Tumor Response to Transarterial Embolization. J Vasc Interv Radiol 2017;28:349-355.e1. [PMID: 28126478 DOI: 10.1016/j.jvir.2016.11.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
306 Kim JH, Sinn DH, Shin SW, Cho SK, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS. The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. Clin Mol Hepatol 2017;23:42-50. [PMID: 28263954 DOI: 10.3350/cmh.2016.0058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
307 Haaga JR, Haaga R, Patel I, Love Z, Moulter J. ALPHA Glycolytic Vasculogenesis Better Correlates With MRI and CT Imaging Techniques Than the Traditional Oxygen Vasculogenesis Theory. American Journal of Roentgenology 2014;203:W724-34. [DOI: 10.2214/ajr.13.11762] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
308 Apisarnthanarax S, Barry A, Cao M, Czito B, DeMatteo R, Drinane M, Hallemeier CL, Koay EJ, Lasley F, Meyer J, Owen D, Pursley J, Schaub SK, Smith G, Venepalli NK, Zibari G, Cardenes H. External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol 2021:S1879-8500(21)00233-2. [PMID: 34688956 DOI: 10.1016/j.prro.2021.09.004] [Reference Citation Analysis]
309 El-Khoueiry A. The Promise of Immunotherapy in the Treatment of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book. 2017;37:311-317. [PMID: 28561676 DOI: 10.14694/edbk_175230] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
310 Kwan SW, Fidelman N, Ma E, Kerlan RK Jr, Yao FY. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl. 2012;18:727-736. [PMID: 22344899 DOI: 10.1002/lt.23413] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 7.4] [Reference Citation Analysis]
311 Delgado TC, Barbier-Torres L, Zubiete-Franco I, Lopitz-Otsoa F, Varela-Rey M, Fernández-Ramos D, Martínez-Chantar ML. Neddylation, a novel paradigm in liver cancer. Transl Gastroenterol Hepatol 2018;3:37. [PMID: 30050997 DOI: 10.21037/tgh.2018.06.05] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
312 Costa FP, de Oliveira AC, Meirelles R, Machado MC, Zanesco T, Surjan R, Chammas MC, de Souza Rocha M, Morgan D, Cantor A, Zimmerman J, Brezovich I, Kuster N, Barbault A, Pasche B. Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. Br J Cancer 2011;105:640-8. [PMID: 21829195 DOI: 10.1038/bjc.2011.292] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
313 Choi J, Lee D, Shim JH, Kim KM, Lim YS, Lee YS, Lee HC. Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma.PLoS One. 2020;15:e0229696. [PMID: 32130270 DOI: 10.1371/journal.pone.0229696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
314 Stevens H, Chyn Chua C, Wallis M, Hew S, Grigg A. Fanconi anemia in 55-year-old identical twins first presenting as fatal post-chemotherapy pancytopenia. Am J Hematol 2016;91:1273-6. [PMID: 27427815 DOI: 10.1002/ajh.24488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
315 Song JE, Kim DY. Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. World J Hepatol 2017; 9(18): 808-814 [PMID: 28706579 DOI: 10.4254/wjh.v9.i18.808] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
316 Lin XJ, Lao XM, Shi M, Li SP. Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment. Dig Dis Sci 2016;61:2465-76. [PMID: 27105647 DOI: 10.1007/s10620-016-4167-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
317 Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol 2015; 21(12): 3462-3471 [PMID: 25834310 DOI: 10.3748/wjg.v21.i12.3462] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
318 Dollinger MM, Behrens CM, Lesske J, Behl S, Behrmann C, Fleig WE. Thymostimulin in advanced hepatocellular carcinoma: a phase II trial. BMC Cancer 2008;8:72. [PMID: 18366627 DOI: 10.1186/1471-2407-8-72] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
319 Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel AB, Dubrovsky L, Kudo M. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. Cardiovasc Intervent Radiol 2022. [PMID: 35119481 DOI: 10.1007/s00270-021-03031-9] [Reference Citation Analysis]
320 Seinstra BA, Defreyne L, Lambert B, Lam MG, Verkooijen HM, van Erpecum KJ, van Hoek B, van Erkel AR, Coenraad MJ, Al Younis I. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Trials. 2012;13:144. [PMID: 22913492 DOI: 10.1186/1745-6215-13-144] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
321 Karanicolas PJ, Ko YJ. Transarterial Therapy for Primary Liver Carcinomas: A Crack in the Armor? Ann Surg Oncol 2015;22:4111-2. [PMID: 26228107 DOI: 10.1245/s10434-015-4776-9] [Reference Citation Analysis]
322 Connell LC, Harding JJ, Abou-Alfa GK. Advanced Hepatocellular Cancer: the Current State of Future Research. Curr Treat Options Oncol. 2016;17:43. [PMID: 27344158 DOI: 10.1007/s11864-016-0415-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
323 Sun Y, Zhai W, Liu X, Song X, Gao X, Xu K, Tang B. Homotypic cell membrane-cloaked biomimetic nanocarrier for the accurate photothermal-chemotherapy treatment of recurrent hepatocellular carcinoma. J Nanobiotechnology 2020;18:60. [PMID: 32299505 DOI: 10.1186/s12951-020-00617-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
324 Koroki K, Ogasawara S, Ooka Y, Kanzaki H, Kanayama K, Maruta S, Maeda T, Yokoyama M, Wakamatsu T, Inoue M, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Kuboki S, Ohtsuka M, Miyazaki M, Yokosuka O, Kato N. Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. Liver Cancer 2020;9:596-612. [PMID: 33083283 DOI: 10.1159/000508809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
325 Kuroda H, Nagasawa T, Fujiwara Y, Sato H, Abe T, Kooka Y, Endo K, Oikawa T, Sawara K, Takikawa Y. Comparing the Safety and Efficacy of Microwave Ablation Using ThermosphereTM Technology versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers (Basel) 2021;13:1295. [PMID: 33803926 DOI: 10.3390/cancers13061295] [Reference Citation Analysis]
326 Katsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, Karnabatidis D. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0184597. [PMID: 28934265 DOI: 10.1371/journal.pone.0184597] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 8.4] [Reference Citation Analysis]
327 Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, Torimura T, Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T; Miriplatin TACE Study Group. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. J Gastroenterol 2018;53:281-90. [PMID: 28766016 DOI: 10.1007/s00535-017-1374-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
328 Kim HY, Park JW. Current immunotherapeutic strategies in hepatocellular carcinoma: recent advances and future directions. Therap Adv Gastroenterol 2017;10:805-14. [PMID: 29051790 DOI: 10.1177/1756283X17722061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
329 Slotta JE, Kollmar O, Ellenrieder V, Ghadimi BM, Homayounfar K. Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives. World J Hepatol 2015; 7(9): 1168-1183 [PMID: 26019733 DOI: 10.4254/wjh.v7.i9.1168] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
330 Jeliazkova P, Umgelter A, Braren R, Kaissis G, Mustafa M, Einwächter H. Prognostic factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization and radioembolization: a retrospective study. Eur J Gastroenterol Hepatol 2020;32:1036-41. [PMID: 31851090 DOI: 10.1097/MEG.0000000000001625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
331 Hiraoka A, Kumagi T, Hirooka M, Uehara T, Kurose K, Iuchi H, Hiasa Y, Matsuura B, Michitaka K, Kumano S, Tanaka H, Yamashita Y, Horiike N, Mochizuki T, Onji M. Prognosis following transcatheter arterial embolization for 121 patients with unresectable hepatocellular carcinoma with or without a history of treatment. World J Gastroenterol 2006; 12(13): 2075-2079 [PMID: 16610060 DOI: 10.3748/wjg.v12.i13.2075] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
332 Zhao YN, Zhang YQ, Ye JZ, Liu X, Yang HZ, Cong FY, Xiang BD, Wu FX, Ma L, Li LQ, Ye HH. Hepatic resection versus transarterial chemoembolization for patients with Barcelona Clinic Liver Cancer intermediate stage Child-Pugh A hepatocellular carcinoma. Exp Ther Med 2016;12:3813-9. [PMID: 28105115 DOI: 10.3892/etm.2016.3810] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
333 Zhu Q, Li N, Zeng X, Han Q, Li F, Yang C, Lv Y, Zhou Z, Liu Z. Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. Oncotarget. 2015;6:4440-4450. [PMID: 25686836 DOI: 10.18632/oncotarget.2913] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
334 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
335 Keane FK, Wo JY, Zhu AX, Hong TS. Liver-Directed Radiotherapy for Hepatocellular Carcinoma. Liver Cancer 2016;5:198-209. [PMID: 27493895 DOI: 10.1159/000367764] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
336 Granito A, Bolondi L. Medical treatment of hepatocellular carcinoma. Mediterr J Hematol Infect Dis 2009;1:e2009021. [PMID: 21415957 DOI: 10.4084/MJHID.2009.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
337 Fateen W, Khan F, O'Neill RJ, James MW, Ryder SD, Aithal GP. Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma. J Hepatocell Carcinoma 2017;4:123-30. [PMID: 29082223 DOI: 10.2147/JHC.S144068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
338 Kong VC, Velec M. Stereotactic Body Radiation Therapy for Liver Cancer: A Review of the Technology. J Med Imaging Radiat Sci 2015;46:343-50. [PMID: 31052142 DOI: 10.1016/j.jmir.2015.06.005] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
339 Bester L, Meteling B, Boshell D, Saxena A, Morris DL. Current role of transarterial chemoembolization and radioembolization in the treatment of metastatic colorectal cancer. Hepat Oncol 2014;1:215-28. [PMID: 30190956 DOI: 10.2217/hep.13.21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
340 Wu J, Song L, Zhao DY, Guo B, Liu J. Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2014; 20(31): 10960-10968 [PMID: 25152600 DOI: 10.3748/wjg.v20.i31.10960] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
341 Kobayashi S, Tajiri K, Murayama A, Entani T, Futsukaichi Y, Nagata K, Takahashi K, Yasuda I. Drug-eluting Bead-Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma Refractory to Conventional Lipiodol-based Transcatheter Arterial Chemoembolization. J Hepatocell Carcinoma 2020;7:181-9. [PMID: 33117752 DOI: 10.2147/JHC.S273929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
342 Kim JS, You CR, Jang JW, Bae SH, Choi JY, Yoon SK, Kay CS. Application of helical tomotherapy for two cases of advanced hepatocellular carcinoma. Korean J Intern Med 2011;26:201-6. [PMID: 21716911 DOI: 10.3904/kjim.2011.26.2.201] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
343 Yamamoto A, Chervoneva I, Sullivan KL, Eschelman DJ, Gonsalves CF, Mastrangelo MJ, Berd D, Shields JA, Shields CL, Terai M, Sato T. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology 2009;252:290-8. [PMID: 19561263 DOI: 10.1148/radiol.2521081252] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
344 Currie BM, Soulen MC. Decision Making: Intra-arterial Therapies for Cholangiocarcinoma-TACE and TARE. Semin Intervent Radiol 2017;34:92-100. [PMID: 28579676 DOI: 10.1055/s-0037-1602591] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
345 Eltawil KM, Berry R, Abdolell M, Molinari M. Quality of life and survival analysis of patients undergoing transarterial chemoembolization for primary hepatic malignancies: a prospective cohort study. HPB (Oxford). 2012;14:341-350. [PMID: 22487072 DOI: 10.1111/j.1477-2574.2012.00455.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
346 Miki I, Murata S, Uchiyama F, Yasui D, Ueda T, Sugihara F, Saito H, Yamaguchi H, Murakami R, Kawamoto C, Uchida E, Kumita SI. Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy. World J Gastroenterol 2017; 23(35): 6437-6447 [PMID: 29085193 DOI: 10.3748/wjg.v23.i35.6437] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
347 Tamura M, Ito H, Matsui H. Radiotherapy for cancer using X-ray fluorescence emitted from iodine. Sci Rep 2017;7:43667. [PMID: 28252657 DOI: 10.1038/srep43667] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
348 Zhao GS, Liu Y, Zhang Q, Li C, Zhang YW, Ren ZZ, Zhou J, Zhang M. Transarterial chemoembolization combined with Huaier granule for the treatment of primary hepatic carcinoma: Safety and efficacy. Medicine (Baltimore) 2017;96:e7589. [PMID: 28723799 DOI: 10.1097/MD.0000000000007589] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
349 Zhang X, Dai F, Chen J, Xie X, Xu H, Bai C, Qiao W, Shen W. Antitumor effect of curcumin liposome after transcatheter arterial embolization in VX2 rabbits. Cancer Biol Ther 2019;20:642-52. [PMID: 30621501 DOI: 10.1080/15384047.2018.1550567] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
350 Yu H, Zhu GY, Xu RZ, Niu HZ, Lu Q, Li GZ, Wang ZY, Zhang DS, Gu N, Teng GJ. Arterial embolization hyperthermia using As2O3 nanoparticles in VX2 carcinoma-induced liver tumors. PLoS One 2011;6:e17926. [PMID: 21448278 DOI: 10.1371/journal.pone.0017926] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
351 Sur BW, Sharma A. Transarterial Chemoembolization for Hepatocellular Carcinoma. Journal of Radiology Nursing 2018;37:107-11. [DOI: 10.1016/j.jradnu.2017.12.004] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
352 Li H, Zhou W, Wei H, Li L, Wang X, Li Y, Li S, Li C. Ferritinophagic Flux Was a Driving Force in Determination of Status of EMT, Ferroptosis, and NDRG1 Activation in Action of Mechanism of 2-Pyridylhydrazone Dithiocarbamate S-Acetic Acid. J Oncol 2021;2021:3015710. [PMID: 34917147 DOI: 10.1155/2021/3015710] [Reference Citation Analysis]
353 Gupta S, Wright KC, Ensor J, Van Pelt CS, Dixon KA, Kundra V. Hepatic Arterial Embolization with Doxorubicin-Loaded Superabsorbent Polymer Microspheres in a Rabbit Liver Tumor Model. Cardiovasc Intervent Radiol 2011;34:1021-30. [DOI: 10.1007/s00270-011-0154-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
354 Lanza E, Donadon M, Poretti D, Pedicini V, Tramarin M, Roncalli M, Rhee H, Park YN, Torzilli G. Transarterial Therapies for Hepatocellular Carcinoma. Liver Cancer 2016;6:27-33. [PMID: 27995085 DOI: 10.1159/000449347] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
355 Malagari K, Pomoni A, Filippiadis D, Kelekis D. Chemoembolization of hepatocellular carcinoma with HepaSphere™. Hepat Oncol 2015;2:147-57. [PMID: 30190994 DOI: 10.2217/hep.15.2] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
356 Mahnken AH, Bruners P, Günther RW. Techniques of interventional tumor therapy. Dtsch Arztebl Int 2008;105:646-53. [PMID: 19471636 DOI: 10.3238/arztebl.2008.0646] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
357 Bai MY, Tang SL, Chuang MH, Wang TY, Hong PD. Evaluation of Chitosan Derivative Microparticles Encapsulating Superparamagnetic Iron Oxide and Doxorubicin as a pH-Sensitive Delivery Carrier in Hepatic Carcinoma Treatment: An in vitro Comparison Study. Front Pharmacol 2018;9:1025. [PMID: 30298001 DOI: 10.3389/fphar.2018.01025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
358 Azzam AZ. Liver transplantation as a management of hepatocellular carcinoma. World J Hepatol 2015; 7(10): 1347-1354 [PMID: 26052380 DOI: 10.4254/wjh.v7.i10.1347] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
359 Cantaloube M, Castan F, Creoff M, Prunaretty J, Bordeau K, Michalet M, Assenat E, Guiu B, Pageaux GP, Ychou M, Aillères N, Fenoglietto P, Azria D, Riou O. Image-Guided Liver Stereotactic Body Radiotherapy Using VMAT and Real-Time Adaptive Tumor Gating: Evaluation of the Efficacy and Toxicity for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4853. [PMID: 34638336 DOI: 10.3390/cancers13194853] [Reference Citation Analysis]
360 Sarno G, Montalti R, Giglio MC, Rompianesi G, Tomassini F, Scarpellini E, De Simone G, De Palma GD, Troisi RI. Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment. Surg Oncol 2021;36:42-50. [PMID: 33307490 DOI: 10.1016/j.suronc.2020.11.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
361 Boily G, Villeneuve JP, Lacoursière L, Chaudhury P, Couture F, Ouellet JF, Lapointe R, Goulet S, Gervais N; Comité de l'évolution des pratiques en oncologie. Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations. HPB (Oxford) 2015;17:52-65. [PMID: 24961288 DOI: 10.1111/hpb.12273] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
362 Högberg J, Rizell M, Hultborn R, Svensson J, Henrikson O, Mölne J, Gjertsson P, Bernhardt P. Heterogeneity of microsphere distribution in resected liver and tumour tissue following selective intrahepatic radiotherapy. EJNMMI Res 2014;4:48. [PMID: 26116112 DOI: 10.1186/s13550-014-0048-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
363 Vivarelli M, Montalti R, Risaliti A. Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update. World J Gastroenterol 2013;19:7316-26. [PMID: 24259963 DOI: 10.3748/wjg.v19.i42.7316] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
364 Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology 2013;58:2188-97. [PMID: 23512791 DOI: 10.1002/hep.26382] [Cited by in Crossref: 109] [Cited by in F6Publishing: 110] [Article Influence: 12.1] [Reference Citation Analysis]
365 Dreher MR, Sharma KV, Woods DL, Reddy G, Tang Y, Pritchard WF, Chiesa OA, Karanian JW, Esparza JA, Donahue D, Levy EB, Willis SL, Lewis AL, Wood BJ. Radiopaque drug-eluting beads for transcatheter embolotherapy: experimental study of drug penetration and coverage in swine. J Vasc Interv Radiol 2012;23:257-64.e4. [PMID: 22178039 DOI: 10.1016/j.jvir.2011.10.019] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 6.7] [Reference Citation Analysis]
366 Abdel-Hamid NM, Abdullah AH. Serum histamine and acetylcholine variations as new noninvasive biochemical markers in staging of experimental hepatocellular carcinoma. Clin Exp Med 2019;19:115-20. [PMID: 30460419 DOI: 10.1007/s10238-018-0537-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
367 Beaton L, Tregidgo HFJ, Znati SA, Forsyth S, Clarkson MJ, Bandula S, Chouhan M, Lowe HL, Zaw Thin M, Hague J, Sharma D, Pollok JM, Davidson BR, Raja J, Munneke G, Stuckey DJ, Bascal ZA, Wilde PE, Cooper S, Ryan S, Czuczman P, Boucher E, Hartley JA, Lewis AL, Jansen M, Meyer T, Sharma RA. VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies. JMIR Res Protoc 2019;8:e13696. [PMID: 31579027 DOI: 10.2196/13696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
368 Sastre J, Díaz-Beveridge R, García-Foncillas J, Guardeño R, López C, Pazo R, Rodriguez-Salas N, Salgado M, Salud A, Feliu J. Clinical guideline SEOM: hepatocellular carcinoma. Clin Transl Oncol 2015;17:988-95. [PMID: 26607931 DOI: 10.1007/s12094-015-1451-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
369 Dai F, Zhang X, Shen W, Chen J, Liu L, Gao G. Liposomal curcumin inhibits hypoxia-induced angiogenesis after transcatheter arterial embolization in VX2 rabbit liver tumors. Onco Targets Ther 2015;8:2601-11. [PMID: 26451117 DOI: 10.2147/OTT.S87931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
370 Zhang Y, Qu S, Yi W, Zhai J, Zhang X, Wei L, Lau WY, Wu M, Shen F, Fan H, Wu D. A Pretreatment CT Model Predicts Survival Following Chemolipiodolization in Patients With Hepatocellular Carcinoma. Technol Cancer Res Treat 2019;18:1533033819844488. [PMID: 31204599 DOI: 10.1177/1533033819844488] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
371 Song DS, Nam SW, Bae SH, Kim JD, Jang JW, Song MJ, Lee SW, Kim HY, Lee YJ, Chun HJ, You YK, Choi JY, Yoon SK. Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2015; 21(8): 2395-2404 [PMID: 25741147 DOI: 10.3748/wjg.v21.i8.2395] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
372 Wang X, Liang H, Lu Z. Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation. Minim Invasive Ther Allied Technol 2020;29:344-52. [PMID: 31375044 DOI: 10.1080/13645706.2019.1649286] [Reference Citation Analysis]
373 Duran R, Chapiro J, Schernthaner RE, Geschwind JF. Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. Br J Radiol. 2015;88:20140564. [PMID: 25978585 DOI: 10.1259/bjr.20140564] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
374 Shi M, Chen JA, Lin XJ, Guo RP, Yuan YF, Chen MS, Zhang YQ, Li JQ. Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World J Gastroenterol 2010; 16(2): 264-269 [PMID: 20066748 DOI: 10.3748/wjg.v16.i2.264] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
375 Young S, Sanghvi T, Sharma S, Richardson C, Rubin N, Richards M, D'Souza D, Flanagan S, Golzarian J. Local recurrence following complete radiologic response in patients treated with transarterial chemoembolization for hepatocellular carcinoma. Diagn Interv Imaging 2022:S2211-5684(22)00006-7. [PMID: 35115276 DOI: 10.1016/j.diii.2022.01.006] [Reference Citation Analysis]
376 Ma W, Jia J, Wang S, Bai W, Yi J, Bai M, Quan Z, Yin Z, Fan D, Wang J, Han G. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Theranostics. 2014;4:736-744. [PMID: 24883123 DOI: 10.7150/thno.8725] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
377 Kim DY, Han KH. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. Hepatol Int 2016;10:883-92. [PMID: 27126821 DOI: 10.1007/s12072-016-9722-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
378 Imai N, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Hirooka Y, Goto H. Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques. World J Hepatol 2014; 6(12): 844-850 [PMID: 25544871 DOI: 10.4254/wjh.v6.i12.844] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
379 Shields A, Reddy KR. Hepatocellular carcinoma: current treatment strategies. Curr Treat Options Gastroenterol 2005;8:457-66. [PMID: 16313863 DOI: 10.1007/s11938-005-0032-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
380 Guan YS, Sun L, Zhou XP, Li X, Zheng XH. Hepatocellular carcinoma treated with interventional procedures: CT and MRI follow-up. World J Gastroenterol 2004; 10(24): 3543-3548 [PMID: 15534903 DOI: 10.3748/wjg.v10.i24.3543] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
381 Yang Y, Jin C, Li H, He Y, Liu Z, Bai L, Dou K. Improved radiosensitizing effect of the combination of etanidazole and paclitaxel for hepatocellular carcinoma in vivo. Exp Ther Med 2012;3:299-303. [PMID: 22969885 DOI: 10.3892/etm.2011.389] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
382 Yang Y, Qin Z, Du D, Wu Y, Qiu S, Mu F, Xu K, Chen J. Safety and Short-Term Efficacy of Irreversible Electroporation and Allogenic Natural Killer Cell Immunotherapy Combination in the Treatment of Patients with Unresectable Primary Liver Cancer. Cardiovasc Intervent Radiol 2019;42:48-59. [PMID: 30151798 DOI: 10.1007/s00270-018-2069-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
383 Osuga K, Maeda N, Higashihara H, Hori S, Nakazawa T, Tanaka K, Nakamura M, Kishimoto K, Ono Y, Tomiyama N. Current status of embolic agents for liver tumor embolization. Int J Clin Oncol 2012;17:306-15. [PMID: 22806426 DOI: 10.1007/s10147-012-0445-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
384 Bilbao JI, Martínez-Cuesta A, Urtasun F, Cosín O. Complications of embolization. Semin Intervent Radiol. 2006;23:126-142. [PMID: 21326756 DOI: 10.1055/s-2006-941443] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
385 Wang J, Wang FW. Refusal of cancer-directed surgery strongly impairs survival of patients with localized hepatocellular carcinoma. Int J Surg Oncol 2010;2010:381795. [PMID: 22312489 DOI: 10.1155/2010/381795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
386 Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, Sato KT, Marshall K, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Senthilnathan S, Baker T, Gates VL, Abecassis M, Benson AB 3rd, Mulcahy MF, Omary RA, Salem R. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011;141:526-35, 535.e1-2. [PMID: 21664356 DOI: 10.1053/j.gastro.2011.04.054] [Cited by in Crossref: 117] [Cited by in F6Publishing: 108] [Article Influence: 10.6] [Reference Citation Analysis]
387 Cho E, Cho HA, Jun CH, Kim HJ, Cho SB, Choi SK. A Review of Hepatocellular Carcinoma in Elderly Patients Focused on Management and Outcomes. In Vivo 2019;33:1411-20. [PMID: 31471386 DOI: 10.21873/invivo.11618] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
388 Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D'Angelica MI, Allen PJ, Erinjeri JP, Brody LA, O'Neill GP, Johnson KN, Garcia AR, Beattie C, Zhao B, Solomon SB, Schwartz LH, DeMatteo R, Abou-Alfa GK. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol. 2016;34:2046-2053. [PMID: 26834067 DOI: 10.1200/jco.2015.64.0821] [Cited by in Crossref: 181] [Cited by in F6Publishing: 84] [Article Influence: 30.2] [Reference Citation Analysis]
389 Orgera G, Monfardini L, Della Vigna P, Zhang L, Bonomo G, Arnone P, Padrenostro M, Orsi F. High-intensity focused ultrasound (HIFU) in patients with solid malignancies: evaluation of feasibility, local tumour response and clinical results. Radiol Med. 2011;116:734-748. [PMID: 21293939 DOI: 10.1007/s11547-011-0634-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
390 Gong F, Xu J, Liu B, Yang N, Cheng L, Huang P, Wang C, Chen Q, Ni C, Liu Z. Nanoscale CaH2 materials for synergistic hydrogen-immune cancer therapy. Chem 2022;8:268-86. [DOI: 10.1016/j.chempr.2021.11.020] [Reference Citation Analysis]
391 Gaba RC, Wang D, Lewandowski RJ, Ryu RK, Sato KT, Kulik LM, Mulcahy MF, Larson AC, Salem R, Omary RA. Four-dimensional transcatheter intraarterial perfusion MR imaging for monitoring chemoembolization of hepatocellular carcinoma: preliminary results. J Vasc Interv Radiol 2008;19:1589-95. [PMID: 18818097 DOI: 10.1016/j.jvir.2008.08.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
392 Northup PG, Abecassis MM, Englesbe MJ, Emond JC, Lee VD, Stukenborg GJ, Tong L, Berg CL; Adult-to-Adult Living Donor Liver Transplantation Cohort Study Group. Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost. Liver Transpl 2009;15:148-62. [PMID: 19177435 DOI: 10.1002/lt.21671] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
393 Buettner S, Ten Cate DWG, Bagante F, Alexandrescu S, Marques HP, Lamelas J, Aldrighetti L, Gamblin TC, Maithel SK, Pulitano C, Margonis GA, Weiss M, Bauer TW, Shen F, Poultsides GA, Marsh JW, IJzermans JNM, Pawlik TM, Koerkamp BG. Survival after Resection of Multiple Tumor Foci of Intrahepatic Cholangiocarcinoma. J Gastrointest Surg 2019;23:2239-46. [PMID: 30887301 DOI: 10.1007/s11605-019-04184-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
394 Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF. [Therapy response of liver tumors after selective internal radiation therapy]. Radiologe. 2008;48:839-849. [PMID: 18766324 DOI: 10.1007/s00117-008-1730-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
395 He Q, Lu WS, Liu Y, Guan YS, Kuang AR. 131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma. World J Gastroenterol 2013; 19(47): 9104-9110 [PMID: 24379637 DOI: 10.3748/wjg.v19.i47.9104] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
396 Welling TH, Eddinger K, Carrier K, Zhu D, Kleaveland T, Moore DE, Schaubel DE, Abt PL. Multicenter Study of Staging and Therapeutic Predictors of Hepatocellular Carcinoma Recurrence Following Transplantation. Liver Transpl. 2018;24:1233-1242. [PMID: 29729113 DOI: 10.1002/lt.25194] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
397 Reyes DK, Vossen JA, Kamel IR, Azad NS, Wahlin TA, Torbenson MS, Choti MA, Geschwind JF. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J 2009;15:526-32. [PMID: 20010173 DOI: 10.1097/PPO.0b013e3181c5214b] [Cited by in Crossref: 88] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
398 Wang D, Gaba RC, Jin B, Riaz A, Lewandowski RJ, Ryu RK, Sato KT, Ragin AB, Kulik LM, Mulcahy MF, Salem R, Larson AC, Omary RA. Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma. Acad Radiol 2011;18:828-36. [PMID: 21669349 DOI: 10.1016/j.acra.2011.02.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
399 Cardarelli-Leite L, Hadjivassiliou A, Klass D, Chung J, Ho SGF, Lim HJ, Kim PTW, Mujoomdar A, Liu DM. Current locoregional therapies and treatment strategies in hepatocellular carcinoma. Curr Oncol 2020;27:S144-51. [PMID: 33343208 DOI: 10.3747/co.27.7171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
400 Song Y, Xing H, Zhou L, Zhang N, Yang M. LncRNA H19 modulated by miR-146b-3p/miR-1539-mediated allelic regulation in transarterial chemoembolization of hepatocellular carcinoma. Arch Toxicol 2021;95:3063-70. [PMID: 34251499 DOI: 10.1007/s00204-021-03119-8] [Reference Citation Analysis]
401 Chiang CL, Chan MKH, Yeung CSY, Ho CHM, Lee FAS, Lee VWY, Wong FCS, Blanck O. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma. Strahlenther Onkol 2019;195:254-64. [PMID: 30413833 DOI: 10.1007/s00066-018-1391-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
402 White SB. Treatment of Hepatocellular Carcinoma: Time for a Paradigm Shift? Radiology 2019;292:760-1. [PMID: 31364953 DOI: 10.1148/radiol.2019191474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
403 Hickey RM, Lewandowski RJ, Salem R. Rationale of transcatheter intra-arterial therapies of hepatic cancers. Hepat Oncol 2014;1:285-91. [PMID: 30190963 DOI: 10.2217/hep.14.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
404 Nishikawa H, Osaki Y, Iguchi E, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Saito S, Nasu A, Kita R, Kimura T. Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma. Exp Ther Med 2012;4:381-6. [PMID: 23181103 DOI: 10.3892/etm.2012.611] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
405 Liu PH, Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI. Uncompromised treatment efficacy in elderly patients with hepatocellular carcinoma: A propensity score analysis. Medicine (Baltimore). 2014;93:e264. [PMID: 25526453 DOI: 10.1097/md.0000000000000264] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
406 Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer 2013;119:3334-42. [PMID: 23821538 DOI: 10.1002/cncr.28209] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
407 Woodrell CD, Hansen L, Schiano TD, Goldstein NE. Palliative Care for People With Hepatocellular Carcinoma, and Specific Benefits for Older Adults. Clin Ther 2018;40:512-25. [PMID: 29571567 DOI: 10.1016/j.clinthera.2018.02.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
408 Spangenberg HC, Mohr L, Blum HE. [Regional therapy of liver tumors]. Internist (Berl). 2007;48:40-45. [PMID: 17160664 DOI: 10.1007/s00108-006-1771-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
409 Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52. [PMID: 19908093 DOI: 10.1007/s00270-009-9711-7] [Cited by in Crossref: 948] [Cited by in F6Publishing: 822] [Article Influence: 72.9] [Reference Citation Analysis]
410 Allen J, Venook A. Hepatocellular carcinoma: epidemic and treatment. Curr Oncol Rep 2004;6:177-83. [PMID: 15066228 DOI: 10.1007/s11912-004-0047-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
411 Riaz A, Lewandowski RJ, Kulik L, Ryu RK, Mulcahy MF, Baker T, Gates V, Nayar R, Wang E, Miller FH. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol. 2010;33:1143-1152. [PMID: 19967371 DOI: 10.1007/s00270-009-9766-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 65] [Article Influence: 5.9] [Reference Citation Analysis]
412 Sun L, Guan YS, Pan WM, Luo ZM, Wei JH, Zhao L, Wu H. Metabolic restaging of hepatocellular carcinoma using whole-body 18F-FDG PET/CT. World J Hepatol 2009; 1(1): 90-97 [PMID: 21160970 DOI: 10.4254/wjh.v1.i1.90] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
413 Yang Y, Si T. Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Biol Med 2018;15:299-310. [PMID: 30197797 DOI: 10.20892/j.issn.2095-3941.2017.0177] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
414 Liu S, Lai J, Lyu N, Xie Q, Cao H, Chen D, He M, Zhang B, Zhao M. Effects of Antiviral Therapy on HBV Reactivation and Survival in Hepatocellular Carcinoma Patients Undergoing Hepatic Artery Infusion Chemotherapy. Front Oncol 2020;10:582504. [PMID: 33614477 DOI: 10.3389/fonc.2020.582504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
415 Jarnagin WR, Schwartz LH, Gultekin DH, Gönen M, Haviland D, Shia J, D'Angelica M, Fong Y, DeMatteo R, Tse A, Blumgart LH, Kemeny N. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 2009;20:1589-95. [PMID: 19491285 DOI: 10.1093/annonc/mdp029] [Cited by in Crossref: 113] [Cited by in F6Publishing: 107] [Article Influence: 8.7] [Reference Citation Analysis]
416 Tezuka M, Hayashi K, Okada Y, Irie T, Ina H. Therapeutic results of computed-tomography-guided transcatheter arterial chemoembolization for local recurrence of hepatocellular carcinoma after initial transcatheter arterial chemoembolization: the results of 85 recurrent tumors in 35 patients. Dig Dis Sci. 2009;54:661-669. [PMID: 18649138 DOI: 10.1007/s10620-008-0388-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
417 Perumalswami PV, Schiano TD. The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. Dig Dis Sci 2011;56:1266-81. [PMID: 21416246 DOI: 10.1007/s10620-011-1619-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
418 Paul SB, Gamanagatti S, Sreenivas V, Chandrashekhara SH, Mukund A, Gulati MS, Gupta AK, Acharya SK. Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: Experience from a tertiary care centre in India. Indian J Radiol Imaging. 2011;21:113-120. [PMID: 21799594 DOI: 10.4103/0971-3026.82294] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
419 Buettner S, van Vugt JL, IJzermans JN, Groot Koerkamp B. Intrahepatic cholangiocarcinoma: current perspectives. Onco Targets Ther. 2017;10:1131-1142. [PMID: 28260927 DOI: 10.2147/ott.s93629] [Cited by in Crossref: 58] [Cited by in F6Publishing: 20] [Article Influence: 11.6] [Reference Citation Analysis]
420 Byun HK, Kim HJ, Im YR, Kim DY, Han K, Seong J. Dose escalation in radiotherapy for incomplete transarterial chemoembolization of hepatocellular carcinoma. Strahlenther Onkol 2020;196:132-41. [DOI: 10.1007/s00066-019-01488-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
421 Ramaswami R, Pinato DJ, Kubota K, Ishizuka M, Arizumi T, Kudo M, Jang JW, Kim YW, Pirisi M, Allara E, Sharma R. Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. Med Oncol 2016;33:114. [PMID: 27601241 DOI: 10.1007/s12032-016-0827-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
422 Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP; American Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford). 2010;12:313-320. [PMID: 20590905 DOI: 10.1111/j.1477-2574.2010.00183.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
423 Lanza E, Muglia R, Bolengo I, Poretti D, D'Antuono F, Ceriani R, Torzilli G, Pedicini V. Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization. PLoS One 2020;15:e0227711. [PMID: 31935255 DOI: 10.1371/journal.pone.0227711] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
424 Binder S, Lewis AL, Löhr JM, Keese M. Extravascular use of drug-eluting beads: A promising approach in compartment-based tumor therapy. World J Gastroenterol 2013; 19(43): 7586-7593 [PMID: 24282349 DOI: 10.3748/wjg.v19.i43.7586] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
425 Yang W, Wang D, Huang L, Chen Y, Wen S, Hong Q, Kang D. Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GRADE Approach. Asian Pac J Cancer Prev 2018;19:2043-55. [PMID: 30139041 DOI: 10.22034/APJCP.2018.19.8.2043] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
426 Rou WS, Lee BS, Moon HS, Lee ES, Kim SH, Lee HY. Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization. World J Gastroenterol 2014; 20(22): 6995-7004 [PMID: 24944494 DOI: 10.3748/wjg.v20.i22.6995] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
427 Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 2005; 11(39): 6104-6109 [PMID: 16273634 DOI: 10.3748/wjg.v11.i39.6104] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 46] [Article Influence: 3.2] [Reference Citation Analysis]
428 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015; 7(5): 738-752 [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 5.1] [Reference Citation Analysis]
429 Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015;6:28453-28462. [PMID: 26164085 DOI: 10.18632/oncotarget.4601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
430 Gbolahan OB, Schacht MA, Beckley EW, LaRoche TP, O'Neil BH, Pyko M. Locoregional and systemic therapy for hepatocellular carcinoma. J Gastrointest Oncol. 2017;8:215-228. [PMID: 28480062 DOI: 10.21037/jgo.2017.03.13] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 7.6] [Reference Citation Analysis]
431 Pesapane F, Nezami N, Patella F, Geschwind JF. New concepts in embolotherapy of HCC. Med Oncol. 2017;34:58. [PMID: 28299645 DOI: 10.1007/s12032-017-0917-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
432 Li L, Yeo W. Value of quality of life analysis in liver cancer: A clinician’s perspective. World J Hepatol 2017; 9(20): 867-883 [PMID: 28804570 DOI: 10.4254/wjh.v9.i20.867] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
433 Zhang H, Xia P, Liu J, Chen Z, Ma W, Yuan Y. ATIC inhibits autophagy in hepatocellular cancer through the AKT/FOXO3 pathway and serves as a prognostic signature for modeling patient survival. Int J Biol Sci 2021;17:4442-58. [PMID: 34803509 DOI: 10.7150/ijbs.65669] [Reference Citation Analysis]
434 Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N, Nishikaku F. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 2009;64:473-483. [PMID: 19104812 DOI: 10.1007/s00280-008-0895-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
435 Roch JA, Palma-Gutierrez J, Lapalus MG, Paillet C, Pilleul F. Irinotecan drug eluting beads used as a treatment of advanced intra hepatic cholangiocarcinoma. J Radiol Case Rep 2008;2:24-7. [PMID: 22470601 DOI: 10.3941/jrcr.v2i4.48] [Reference Citation Analysis]
436 Sanoff HK, Chang Y, Stavas JM, Stürmer T, Lund J. Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries. J Natl Compr Canc Netw 2015;13:1102-10. [PMID: 26358794 DOI: 10.6004/jnccn.2015.0135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
437 Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G. Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach. Int J Mol Sci 2019;20:E1465. [PMID: 30909504 DOI: 10.3390/ijms20061465] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
438 Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17:1226-1233. [PMID: 20405327 DOI: 10.1245/s10434-010-0978-3] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
439 Yu X, Ge N, Guo X, Shen S, Liang J, Huang X, Wan S, Xing J, Huang Q, Yang Y. Genetic variants in the EPCAM gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma with portal vein tumor thrombus. PLoS One 2014;9:e93416. [PMID: 24718422 DOI: 10.1371/journal.pone.0093416] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
440 Tamai Y, Iwasa M, Eguchi A, Shigefuku R, Sugimoto K, Hasegawa H, Takei Y. Serum copper, zinc and metallothionein serve as potential biomarkers for hepatocellular carcinoma. PLoS One 2020;15:e0237370. [PMID: 32857769 DOI: 10.1371/journal.pone.0237370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
441 Waghray A, Murali AR, Menon KN. Hepatocellular carcinoma: From diagnosis to treatment. World J Hepatol 2015; 7(8): 1020-1029 [PMID: 26052391 DOI: 10.4254/wjh.v7.i8.1020] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 11.6] [Reference Citation Analysis]
442 Pan CT, Chien ST, Chiang TC, Yen CK, Wang SY, Wen ZH, Yu CY, Shiue YL. Optimization of the spherical integrity for sustained-release alginate microcarriers-encapsulated doxorubicin by the Taguchi method. Sci Rep 2020;10:21758. [PMID: 33303895 DOI: 10.1038/s41598-020-78813-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
443 Chen RX, Gan YH, Ge NL, Chen Y, Ma M, Zhang BH, Wang YH, Ye SL, Luo JF, Ren ZG. A new prediction model for prognosis of patients with intermediate-stage HCC after conventional transarterial chemoembolization: an internally validated study. J Cancer 2019;10:6535-42. [PMID: 31777583 DOI: 10.7150/jca.34064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
444 Xu D, Liu X, Wang L, Xing B. Hepatectomy plus adjuvant transcatheter arterial chemoembolization improves the survival rate of patients with multicentric occurrence of hepatocellular carcinoma. Oncol Lett 2018;16:5882-90. [PMID: 30344739 DOI: 10.3892/ol.2018.9333] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
445 Mokdad AA, Singal AG, Yopp AC. Advances in Local and Systemic Therapies for Hepatocellular Cancer. Curr Oncol Rep 2016;18:9. [PMID: 26769114 DOI: 10.1007/s11912-015-0494-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
446 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Reference Citation Analysis]
447 Yeh MM, Yeung RS, Apisarnthanarax S, Bhattacharya R, Cuevas C, Harris WP, Hon TLK, Padia SA, Park JO, Riggle KM, Daoud SS. Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol 2015; 7(11): 1460-1483 [PMID: 26085907 DOI: 10.4254/wjh.v7.i11.1460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
448 Doemel LA, Santana JG, Savic LJ, Gaupp FML, Borde T, Petukhova-Greenstein A, Kucukkaya AS, Schobert IT, Hamm CA, Gebauer B, Walsh JJ, Rexha I, Hyder F, Lin M, Madoff DC, Schlachter T, Chapiro J, Coman D. Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model. Eur Radiol 2021. [PMID: 34718844 DOI: 10.1007/s00330-021-08337-3] [Reference Citation Analysis]
449 Shi Y, Zhai B. A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma. Gastrointest Tumors 2016;3:90-102. [PMID: 27904861 DOI: 10.1159/000445888] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
450 Perkons NR, Kiefer RM, Noji MC, Pourfathi M, Ackerman D, Siddiqui S, Tischfield D, Profka E, Johnson O, Pickup S, Mancuso A, Pantel A, Denburg MR, Nadolski GJ, Hunt SJ, Furth EE, Kadlecek S, Gade TPF. Hyperpolarized Metabolic Imaging Detects Latent Hepatocellular Carcinoma Domains Surviving Locoregional Therapy. Hepatology 2020;72:140-54. [PMID: 31553806 DOI: 10.1002/hep.30970] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
451 Chen S, Jin H, Dai Z, Wei M, Xiao H, Su T, Li B, Liu X, Wang Y, Li J, Shen S, Zhou Q, Peng B, Peng Z, Peng S. Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma. Cancer Med 2019;8:1530-9. [PMID: 30864247 DOI: 10.1002/cam4.2038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
452 Raees A, Kamran M, Özkan H, Jafri W. Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian J Hepatogastroenterol 2021;11:32-40. [PMID: 34316462 DOI: 10.5005/jp-journals-10018-1335] [Reference Citation Analysis]
453 Cascella T, Garanzini EM, Lanocita R, Morosi C, Riva F, Greco G, Sposito C, Mazzaferro V, Marchianò A, Spreafico C. Long Term Survival Analysis in a Cohort of 125 Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using Small Drug Eluting Beads. Cardiovasc Intervent Radiol 2022;45:54-61. [PMID: 34820694 DOI: 10.1007/s00270-021-02991-2] [Reference Citation Analysis]
454 Chen L, Ni CF, Chen SX, Cao JM, Zhu HD, Guo JH, Zhu GY, Zhong BY, Ding W, He SC, Deng G, Teng GJ. A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients. J Vasc Interv Radiol 2016;27:1288-97. [PMID: 27013402 DOI: 10.1016/j.jvir.2015.12.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
455 Sefrioui D, Verdier V, Savoye-Collet C, Beaussire L, Ghomadi S, Gangloff A, Goria O, Riachi G, Montialoux H, Schwarz L, Tuech JJ, Frebourg T, Michel P, Sarafan-Vasseur N, Di Fiore F. Circulating DNA changes are predictive of disease progression after transarterial chemoembolization. Int J Cancer 2021. [PMID: 34622951 DOI: 10.1002/ijc.33829] [Reference Citation Analysis]
456 Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut. 2018;67:380-388. [PMID: 29150490 DOI: 10.1136/gutjnl-2017-315068] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 16.4] [Reference Citation Analysis]
457 Kakodkar R, Soin AS. Liver Transplantation for HCC: A Review. Indian J Surg. 2012;74:100-117. [PMID: 23372314 DOI: 10.1007/s12262-011-0387-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
458 Aquina CT, Eskander MF, Pawlik TM. Liver-Directed Treatment Options Following Liver Tumor Recurrence: A Review of the Literature. Front Oncol 2022;12:832405. [DOI: 10.3389/fonc.2022.832405] [Reference Citation Analysis]
459 Wang Z, Chen R, Duran R, Zhao Y, Yenokyan G, Chapiro J, Schernthaner R, Radaelli A, Lin M, Geschwind JF. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2015;38:1548-56. [PMID: 26001366 DOI: 10.1007/s00270-015-1129-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
460 Sun B, Zheng CS, Feng GS, Wang Y, Xia XW, Kan XF. Radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis. Shijie Huaren Xiaohua Zazhi 2011; 19(31): 3255-3263 [DOI: 10.11569/wcjd.v19.i31.3255] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
461 Gade TPF, Tucker E, Nakazawa MS, Hunt SJ, Wong W, Krock B, Weber CN, Nadolski GJ, Clark TWI, Soulen MC, Furth EE, Winkler JD, Amaravadi RK, Simon MC. Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma. Radiology 2017;283:702-10. [PMID: 28253108 DOI: 10.1148/radiol.2017160728] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
462 Dansey K, Wooster M, Powell A, Rodriguez E, Zwiebel B, Shames M. Rapid aneurysm growth after transarterial chemoembolization. J Vasc Surg Cases 2015;1:65-7. [PMID: 31724565 DOI: 10.1016/j.jvsc.2014.12.003] [Reference Citation Analysis]
463 Pan CT, Yu RS, Yang CJ, Chen LR, Wen ZH, Chen NY, Ou HY, Yu CY, Shiue YL. Sustained-Release and pH-Adjusted Alginate Microspheres-Encapsulated Doxorubicin Inhibit the Viabilities in Hepatocellular Carcinoma-Derived Cells. Pharmaceutics 2021;13:1417. [PMID: 34575492 DOI: 10.3390/pharmaceutics13091417] [Reference Citation Analysis]
464 Miyayama S, Yamashiro M, Nagai K, Yokka A, Yoshida M, Sakuragawa N, Sanada T, Notsumata K. Excretion of necrotic hepatocellular carcinoma tissues into the biliary system after transcatheter arterial chemoembolization. Hepatol Res 2017;47:1390-6. [PMID: 28229504 DOI: 10.1111/hepr.12880] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
465 Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, Palmer D, Pinato DJ, Sharma R, Ottaviani D, Jang JW, Labeur TA, van Delden OM, Pirisi M, Stern N, Sangro B, Meyer T, Fateen W, García-Fiñana M, Gomaa A, Waked I, Rewisha E, Aithal GP, Travis S, Kudo M, Cucchetti A, Peck-Radosavljevic M, Takkenberg RB, Chan SL, Vogel A, Johnson PJ. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. Hepatology 2020;72:198-212. [PMID: 31698504 DOI: 10.1002/hep.31022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 13.5] [Reference Citation Analysis]
466 Liu C, Li L, Lu WS, Du H, Yan LN, Yang JY, Wen TF, Zeng GJ, Jiang L, Yang J. Neutrophil-lymphocyte Ratio Plus Prognostic Nutritional Index Predicts the Outcomes of Patients with Unresectable Hepatocellular Carcinoma After Transarterial Chemoembolization. Sci Rep 2017;7:13873. [PMID: 29066730 DOI: 10.1038/s41598-017-13239-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
467 Patel K, Lamm R, Altshuler P, Dang H, Shah AP. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy. Int J Mol Sci 2020;21:E6757. [PMID: 32942580 DOI: 10.3390/ijms21186757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
468 Sun XY, Jiang X, Jiang HC. Novel therapeutic strategies targeting the hypoxic microenvironment of tumors. Shijie Huaren Xiaohua Zazhi 2010; 18(17): 1741-1746 [DOI: 10.11569/wcjd.v18.i17.1741] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
469 Hong YM, Yoon KT, Cho M, Kang DH, Kim HW, Choi CW, Park SB, Heo J, Woo HY, Lim W, Bakhtiar Ui Islam SM. Bone marrow metastasis presenting as bicytopenia originating from hepatocellular carcinoma. Clin Mol Hepatol 2016;22:267-71. [PMID: 27184470 DOI: 10.3350/cmh.2015.0017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
470 Zhao JD, Liu J, Ren ZG, Gu K, Zhou ZH, Li WT, Chen Z, Xu ZY, Liu LM, Jiang GL. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. Radiat Oncol. 2010;5:12. [PMID: 20149262 DOI: 10.1186/1748-717X-5-12] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
471 Solomon BL, Garrido-Laguna I. Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. Future Oncol 2018;14:947-62. [PMID: 29542354 DOI: 10.2217/fon-2017-0597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
472 Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer 2021;10:181-223. [PMID: 34239808 DOI: 10.1159/000514174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
473 Vogl TJ, Nour-Eldin NE, Emad-Eldin S, Naguib NN, Trojan J, Ackermann H, Abdelaziz O. Portal vein thrombosis and arterioportal shunts: Effects on tumor response after chemoembolization of hepatocellular carcinoma. World J Gastroenterol 2011; 17(10): 1267-1275 [PMID: 21455325 DOI: 10.3748/wjg.v17.i10.1267] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
474 Baba Y, Hayashi S, Ueno K, Nakajo M, Ueno S, Kubo F, Baba Y, Hamanoue M, Hasegawa S, Tsubouchi H, Komorizono Y. Comparison of survival rates between patients treated with transcatheter arterial chemoembolization and hepatic resection for solitary hepatocellular carcinoma. Oncol Lett 2010;1:905-11. [PMID: 22966404 DOI: 10.3892/ol_00000161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
475 Nishikawa H, Osaki Y, Kita R, Kimura T. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan. Cancers (Basel) 2012;4:165-83. [PMID: 24213234 DOI: 10.3390/cancers4010165] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
476 Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, Mulcahy MF. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497-507.e2. [PMID: 21044630 DOI: 10.1053/j.gastro.2010.10.049] [Cited by in Crossref: 390] [Cited by in F6Publishing: 366] [Article Influence: 32.5] [Reference Citation Analysis]
477 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
478 Raoul JL, Boucher E, Rolland Y, Garin E. Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nat Rev Gastroenterol Hepatol 2010;7:41-9. [PMID: 20051971 DOI: 10.1038/nrgastro.2009.202] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
479 Kim AY, Frantz S, Krishnan P, DeMulder D, Caridi T, Lynskey GE, Spies JB. Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System® for the treatment of hepatocellular carcinoma. PLoS One 2017;12:e0183861. [PMID: 28863147 DOI: 10.1371/journal.pone.0183861] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
480 Wong CC, Kai AK, Ng IO. The impact of hypoxia in hepatocellular carcinoma metastasis. Front Med 2014;8:33-41. [PMID: 24234682 DOI: 10.1007/s11684-013-0301-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 5.3] [Reference Citation Analysis]
481 She WH, Cheung TT, Yau TC, Chan AC, Chok KS, Chu FS, Liu RK, Poon RT, Chan SC, Fan ST, Lo CM. Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection. Hepatobiliary Surg Nutr. 2014;3:185-193. [PMID: 25202695 DOI: 10.3978/j.issn.2304-3881.2014.07.09] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
482 Wang D, Jin B, Lewandowski RJ, Ryu RK, Sato KT, Mulcahy MF, Kulik LM, Miller FH, Salem R, Li D, Omary RA, Larson AC. Quantitative 4D transcatheter intraarterial perfusion MRI for monitoring chemoembolization of hepatocellular carcinoma. J Magn Reson Imaging 2010;31:1106-16. [PMID: 20432345 DOI: 10.1002/jmri.22155] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
483 Liu D, Liu F, Xie X, Su L, Liu M, Kuang M, Huang G, Wang Y, Zhou H, Wang K, Lin M, Tian J. Accurate prediction of responses to transarterial chemoembolization for patients with hepatocellular carcinoma by using artificial intelligence in contrast-enhanced ultrasound. Eur Radiol. 2020;30:2365-2376. [PMID: 31900703 DOI: 10.1007/s00330-019-06553-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 13.5] [Reference Citation Analysis]
484 Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res 2015;45:59-74. [PMID: 24965914 DOI: 10.1111/hepr.12378] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 6.5] [Reference Citation Analysis]
485 Casadei Gardini A, Tamburini E, Iñarrairaegui M, Frassineti GL, Sangro B. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. Onco Targets Ther 2018;11:7315-21. [PMID: 30498358 DOI: 10.2147/OTT.S175715] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
486 Hatanaka T, Arai H, Kakizaki S. Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Hepatol 2018; 10(7): 485-495 [PMID: 30079135 DOI: 10.4254/wjh.v10.i7.485] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
487 Wang C, Liao Y, Qiu J, Yuan Y, Zhang Y, Li K, Zou R, Wang Y, Zuo D, He W, Zheng Y, Li B, Yuan Y. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study. J Cancer Res Clin Oncol 2020;146:2669-80. [PMID: 32449005 DOI: 10.1007/s00432-020-03254-2] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
488 Park SJ, Kim CH, Kim JD, Um SH, Yim SY, Seo MH, Lee DI, Kang JH, Keum B, Kim YS. Spinal cord injury after conducting transcatheter arterial chemoembolization for costal metastasis of hepatocellular carcinoma. Clin Mol Hepatol. 2012;18:316-320. [PMID: 23091813 DOI: 10.3350/cmh.2012.18.3.316] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
489 Goode JA, Matson MB. Embolisation of cancer: what is the evidence? Cancer Imaging 2004;4:133-41. [PMID: 18250022 DOI: 10.1102/1470-7330.2004.0021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
490 Elsayed M, Loya M, Galt J, Schuster DM, Bercu ZL, Newsome J, Brandon D, Benenati S, Behbahani K, Duszak R, Sethi I, Kokabi N. Same day yttrium-90 radioembolization with single photon emission computed tomography/computed tomography: An opportunity to improve care during the COVID-19 pandemic and beyond. World J Gastrointest Oncol 2021; 13(5): 440-452 [PMID: 34040704 DOI: 10.4251/wjgo.v13.i5.440] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
491 He CB, Lin XJ. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101. PLoS One 2017;12:e0174769. [PMID: 28355305 DOI: 10.1371/journal.pone.0174769] [Cited by in Crossref: 22] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
492 Hatanaka T, Naganuma A, Kakizaki S. Lenvatinib for Hepatocellular Carcinoma: A Literature Review. Pharmaceuticals (Basel) 2021;14:36. [PMID: 33418941 DOI: 10.3390/ph14010036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
493 Cormier J, Thomas K, Chari R, Pinson C. Management of Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery 2006;10:761-80. [DOI: 10.1016/j.gassur.2005.10.006] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 3.8] [Reference Citation Analysis]
494 Liang B, Xiang H, Ma C, Xiong B, Ma Y, Zhao C, Yao Y, Zhang Z, Chen C, Li H, Long Q, Zhou J, Luo C, Qiu H, Hu H, Zhao H, Zhou G, Zheng C. Comparison of chemoembolization with CalliSpheres® microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study. Cancer Manag Res 2020;12:941-56. [PMID: 32104076 DOI: 10.2147/CMAR.S187203] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
495 Scartozzi M, Baroni GS, Faloppi L, Paolo MD, Pierantoni C, Candelari R, Berardi R, Antognoli S, Mincarelli C, Risaliti A. Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. J Exp Clin Cancer Res. 2010;29:164. [PMID: 21159184 DOI: 10.1186/1756-9966-29-164] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
496 Yasui D, Yamane A, Itoh H, Kobayashi M, Kumita SI. In vivo evaluation of a monodisperse solid-in-oil-in-water miriplatin/ lipiodol emulsion in transcatheter arterial chemoembolization using a rabbit VX2 tumor model. PLoS One 2020;15:e0222553. [PMID: 32756561 DOI: 10.1371/journal.pone.0222553] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
497 Peungjesada S, Chuang HH, Prasad SR, Choi H, Loyer EM, Bronstein Y. Evaluation of cancer treatment in the abdomen: Trends and advances. World J Radiol 2013; 5(3): 126-142 [PMID: 23671749 DOI: 10.4329/wjr.v5.i3.126] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
498 Nguyen K, Jack K, Sun W. Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy. Diseases 2015;4:E1. [PMID: 28933381 DOI: 10.3390/diseases4010001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
499 Huang WK, Yang SF, You LN, Liu M, Liu DY, Gu P, Fan XW. Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE. Contemp Oncol (Pozn) 2016;20:468-74. [PMID: 28239285 DOI: 10.5114/wo.2016.65607] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
500 Miksad RA, Ogasawara S, Xia F, Fellous M, Piscaglia F. Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. BMC Cancer 2019;19:795. [PMID: 31409405 DOI: 10.1186/s12885-019-5989-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
501 Mikami E, Kanno N, Ueno Y, Shimosegawa T. Retrospective evaluation of tumor-mass-reduction therapy for the prognosis of recurrent hepatocellular carcinoma. Hepatol Int 2007;1:460-8. [PMID: 19669343 DOI: 10.1007/s12072-007-9021-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
502 Kudo M, Han KH, Ye SL, Zhou J, Huang YH, Lin SM, Wang CK, Ikeda M, Chan SL, Choo SP, Miyayama S, Cheng AL. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer 2020;9:245-60. [PMID: 32647629 DOI: 10.1159/000507370] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
503 Chockalingam A, Duran R, Sohn JH, Schernthaner R, Chapiro J, Lee H, Sahu S, Nguyen S, Geschwind JF, Lin M. Radiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of ROI placement. Eur Radiol 2016;26:103-13. [PMID: 25994198 DOI: 10.1007/s00330-015-3812-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
504 Gogia S, Befeler AS. Treating hepatocellular carcinoma without liver transplantation. Curr Gastroenterol Rep 2009;11:69-75. [PMID: 19166662 DOI: 10.1007/s11894-009-0011-9] [Reference Citation Analysis]
505 Valle JW, Dangoor A, Beech J, Sherlock DJ, Lee SM, Scarffe JH, Swindell R, Ranson M. Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. Br J Cancer 2005;92:628-30. [PMID: 15700038 DOI: 10.1038/sj.bjc.6602394] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
506 Kim GH, Kim JH, Kim PH, Chu HH, Gwon DI, Ko HK. Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective. Korean J Radiol 2021;22:1822-33. [PMID: 34431250 DOI: 10.3348/kjr.2021.0229] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
507 Rodenbach M, Eyol E, Seelig MH, Berger MR. Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine. J Cancer Res Clin Oncol. 2005;131:289-299. [PMID: 15657768 DOI: 10.1007/s00432-004-0643-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
508 Sapir E, Tao Y, Schipper MJ, Bazzi L, Novelli PM, Devlin P, Owen D, Cuneo KC, Lawrence TS, Parikh ND, Feng M. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2018;100:122-130. [PMID: 29066120 DOI: 10.1016/j.ijrobp.2017.09.001] [Cited by in Crossref: 66] [Cited by in F6Publishing: 50] [Article Influence: 13.2] [Reference Citation Analysis]
509 Lv N, Kong Y, Mu L, Pan T, Xie Q, Zhao M. Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial. Eur Radiol. 2016;26:3492-3499. [PMID: 26801163 DOI: 10.1007/s00330-016-4207-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
510 Weng Z, Ertle J, Zheng S, Lauenstein T, Mueller S, Bockisch A, Gerken G, Yang D, Schlaak JF. Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma. Oncol Lett 2013;6:1707-12. [PMID: 24260066 DOI: 10.3892/ol.2013.1612] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
511 Yu JI, Park HC. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2016; 22(30): 6851-6863 [PMID: 27570422 DOI: 10.3748/wjg.v22.i30.6851] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
512 Sohn W, Ham CB, Kim NH, Kim HJ, Cho YK, Jeon WK, Kim BI. Effect of acute kidney injury on the patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS One 2020;15:e0243780. [PMID: 33315944 DOI: 10.1371/journal.pone.0243780] [Reference Citation Analysis]
513 Gao S, Zhang PJ, Guo JH, Chen H, Xu HF, Liu P, Yang RJ, Zhu X. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients. World J Gastroenterol 2015; 21(36): 10443-10452 [PMID: 26420971 DOI: 10.3748/wjg.v21.i36.10443] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
514 Sacco R, Bertini M, Petruzzi P, Bertoni M, Bargellini I, Bresci G, Federici G, Gambardella L, Metrangolo S, Parisi G, Romano A, Scaramuzzino A, Tumino E, Silvestri A, Altomare E, Vignali C, Capria A. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: A cohort study. World J Gastroenterol 2009; 15(15): 1843-1848 [PMID: 19370781 DOI: 10.3748/wjg.15.1843] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
515 Ahmad J, Rhee J, Carr BI. The Effects of Hepatic Artery Chemotherapy on Viral Hepatitis in Patients With Hepatocellular Carcinoma. Dig Dis Sci 2005;50:331-5. [DOI: 10.1007/s10620-005-1606-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
516 Elsaid NAE, Kaddah RO, Fattah MSA, Salama NM. Subtraction MRI versus diffusion weighted imaging: Which is more accurate in assessment of hepatocellular carcinoma after Trans Arterial Chemoembolization (TACE)? The Egyptian Journal of Radiology and Nuclear Medicine 2016;47:1251-64. [DOI: 10.1016/j.ejrnm.2016.07.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
517 Fu J, Zhang JY, Wang FS. Tamibarotene: a new hope for therapeutic efficacy in hepatocellular carcinoma patients. Hepatol Int 2014;8:1-3. [PMID: 26202399 DOI: 10.1007/s12072-013-9493-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
518 Molvar C, Lewandowski R. Yttrium-90 Radioembolization of Hepatocellular Carcinoma-Performance, Technical Advances, and Future Concepts. Semin Intervent Radiol 2015;32:388-97. [PMID: 26622103 DOI: 10.1055/s-0035-1564704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
519 Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66:545-551. [PMID: 27816492 DOI: 10.1016/j.jhep.2016.10.029] [Cited by in Crossref: 296] [Cited by in F6Publishing: 296] [Article Influence: 49.3] [Reference Citation Analysis]
520 Wen T, Jin C, Facciorusso A, Donadon M, Han HS, Mao Y, Dai C, Cheng S, Zhang B, Peng B, Du S, Jia C, Xu F, Shi J, Sun J, Zhu P, Nara S, Millis JM; MDT of West China Hospital*. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr 2018;7:353-71. [PMID: 30498711 DOI: 10.21037/hbsn.2018.08.01] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
521 Au JS, Frenette CT. Management of Hepatocellular Carcinoma: Current Status and Future Directions. Gut Liver. 2015;9:437-448. [PMID: 26087860 DOI: 10.5009/gnl15022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
522 Sung PS, Bae SH, Jang JW, Song DS, Kim HY, Yoo SH, Park CH, Kwon JH, Song MJ, You CR, Choi JY, Yoon SK. Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization. Korean J Hepatol 2011;17:299-306. [PMID: 22310794 DOI: 10.3350/kjhep.2011.17.4.299] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
523 Tanaka K. Resection versus transplantation for hepatocellular carcinoma exceeding Milan criteria within increasing donor shortage. Hepatobiliary Surg Nutr 2017;6:280-3. [PMID: 28848755 DOI: 10.21037/hbsn.2017.03.14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
524 Wei G, Yang J. Advances in the treatment of hepatocellular carcinoma using drug-eluting beads. J Interv Med 2020;3:122-7. [PMID: 34805921 DOI: 10.1016/j.jimed.2020.07.003] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
525 Lee JH, Lee YS, Kim PN, Lee BH, Kim GW, Yoo HW, Heo NY, Lim YS, Lee HC, Chung YH, Suh DJ. Osler-Weber-Rendu disease presenting with hepatocellular carcinoma: radiologic and genetic findings. Korean J Hepatol 2011;17:313-8. [PMID: 22310796 DOI: 10.3350/kjhep.2011.17.4.313] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
526 Ma X, Li RS, Wang J, Huang YQ, Li PY, Wang J, Su HB, Wang RL, Zhang YM, Liu HH, Zhang CE, Ma ZJ, Wang JB, Zhao YL, Xiao XH. The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis. Front Pharmacol 2016;7:70. [PMID: 27065861 DOI: 10.3389/fphar.2016.00070] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
527 Makary MS, Khandpur U, Cloyd JM, Mumtaz K, Dowell JD. Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers (Basel) 2020;12:E1914. [PMID: 32679897 DOI: 10.3390/cancers12071914] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
528 Chien SC, Chen CY, Cheng PN, Liu YS, Cheng HC, Chuang CH, Chang TT, Chiu HC, Lin YJ, Chiu YC. Combined Transarterial Embolization/Chemoembolization-Based Locoregional Treatment with Sorafenib Prolongs the Survival in Patients with Advanced Hepatocellular Carcinoma and Preserved Liver Function: A Propensity Score Matching Study. Liver Cancer 2019;8:186-202. [PMID: 31192155 DOI: 10.1159/000489790] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
529 Lock MI, Klein J, Chung HT, Herman JM, Kim EY, Small W, Mayr NA, Lo SS. Strategies to tackle the challenges of external beam radiotherapy for liver tumors. World J Hepatol 2017; 9(14): 645-656 [PMID: 28588749 DOI: 10.4254/wjh.v9.i14.645] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
530 Emond JC, Samstein B, Renz JF. A critical evaluation of hepatic resection in cirrhosis: optimizing patient selection and outcomes. World J Surg. 2005;29:124-130. [PMID: 15654659 DOI: 10.1007/s00268-004-7633-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
531 Xie ZB, Ma L, Wang XB, Bai T, Ye JZ, Zhong JH, Li LQ. Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. Tumour Biol. 2014;35:8451-8459. [PMID: 25038916 DOI: 10.1007/s13277-014-2340-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
532 Van Ha TG. Transarterial chemoembolization for hepatocellular carcinoma. Semin Intervent Radiol 2009;26:270-5. [PMID: 21326572 DOI: 10.1055/s-0029-1225672] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
533 Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol 2014;4:S3-S26. [PMID: 25755608 DOI: 10.1016/j.jceh.2014.04.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
534 Bishay VL, Maglione K, Khanna R, Lee KM, Fischman AM, Lookstein RA, Kim E. Chemoembolization with drug-eluting microspheres (DEM-TACE) for hepatocellular carcinoma: single-center review of safety and efficacy. J Hepatocell Carcinoma 2014;1:187-93. [PMID: 27508187 DOI: 10.2147/JHC.S71602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
535 Sag AA, Selcukbiricik F, Mandel NM. Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. World J Gastroenterol 2016; 22(11): 3127-3149 [PMID: 27003990 DOI: 10.3748/wjg.v22.i11.3127] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
536 Zalinski S, Scatton O, Randone B, Vignaux O, Dousset B. Complete hepatocellular carcinoma necrosis following sequential porto-arterial embolization. World J Gastroenterol 2008; 14(44): 6869-6872 [PMID: 19058317 DOI: 10.3748/wjg.14.6869] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
537 Liu W, Zhou J, Sun Y, Zhang L, Xing B. Hepatic Resection Improved the Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma in Asia: a Systematic Review and Meta-Analysis. J Gastrointest Surg 2015;19:1271-80. [DOI: 10.1007/s11605-015-2811-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
538 Xie F, Zang J, Guo X, Xu F, Shen R, Yan L, Yang J, He J. Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2012;138:455-62. [DOI: 10.1007/s00432-011-1117-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
539 Wang J, Wang F, Kessinger A. Outcome of Combined Hepatocellular and Cholangiocarcinoma of the Liver. J Oncol. 2010;2010:1-7. [PMID: 20871663 DOI: 10.1155/2010/917356] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
540 Kim HY, Park JW. Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. Liver Cancer. 2014;3:9-17. [PMID: 24804173 DOI: 10.1159/000343854] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
541 Kim HY, Kim JD, Bae SH, Park JY, Han KH, Woo HY, Choi JY, Yoon SK, Jang BK, Hwang JS, Kim SG, Kim YS, Seo YS, Yim HJ, Um SH; Korean Liver Cancer Study Group. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. Korean J Hepatol 2010;16:355-61. [PMID: 21415578 DOI: 10.3350/kjhep.2010.16.4.355] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
542 Lencioni R, Marrero J, Venook A, Ye SL, Kudo M. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract. 2010;64:1034-1041. [PMID: 20642705 DOI: 10.1111/j.1742-1241.2010.02414.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 5.1] [Reference Citation Analysis]
543 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in Crossref: 684] [Cited by in F6Publishing: 685] [Article Influence: 57.0] [Reference Citation Analysis]
544 Zhou LH, Peng JH, Qian K, Qian J. Combined use of mitomycin, lipiodol and hepatic artery ligation for treating liver cancer in rats. Shijie Huaren Xiaohua Zazhi 2012; 20(17): 1542-1546 [DOI: 10.11569/wcjd.v20.i17.1542] [Reference Citation Analysis]
545 Defreyne L. Interventional radiology for liver diseases. Eur Radiol 2021;31:2227-30. [PMID: 33009937 DOI: 10.1007/s00330-020-07356-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
546 Faltermeier C, Busuttil RW, Zarrinpar A. A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases 2015;3:221-52. [PMID: 28943622 DOI: 10.3390/diseases3040221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
547 Kim JH, Sinn DH, Lee JH, Hyun D, Cho SK, Shin SW, Chang Y, Kim YJ, Yoon JH, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS. Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. Dig Dis Sci. 2018;63:1062-1071. [PMID: 29442276 DOI: 10.1007/s10620-018-4934-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
548 Sugino Y, Yamakado K, Yamanaka T, Fujimori M, Nakatsuka A, Takaki H, Takei Y, Sakuma H, Isaji S. Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma. Jpn J Radiol 2017;35:254-61. [PMID: 28357723 DOI: 10.1007/s11604-017-0628-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
549 Patel AS, Saeed M, Yee EJ, Yang J, Lam GJ, Losey AD, Lillaney PV, Thorne B, Chin AK, Malik S, Wilson MW, Chen XC, Balsara NP, Hetts SW. Development and Validation of Endovascular Chemotherapy Filter Device for Removing High-Dose Doxorubicin: Preclinical Study. J Med Device 2014;8:0410081-410088. [PMID: 25653735 DOI: 10.1115/1.4027444] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
550 Torimura T, Iwamoto H. Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects. Clin Mol Hepatol 2021;27:236-45. [PMID: 33317248 DOI: 10.3350/cmh.2020.0204] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
551 Apisarnthanarax S, Saini J, O'Ryan-Blair A, Castro J, Bowen SR. Intensity Modulated Proton Therapy with Advanced Planning Techniques in a Challenging Hepatocellular Carcinoma Patient. Cureus 2017;9:e1674. [PMID: 29152431 DOI: 10.7759/cureus.1674] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
552 Loffroy R, Lin M, Yenokyan G, Rao PP, Bhagat N, Noordhoek N, Radaelli A, Blijd J, Liapi E, Geschwind JF. Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma? Radiology. 2013;266:636-648. [PMID: 23143027 DOI: 10.1148/radiol.12112316] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 7.1] [Reference Citation Analysis]
553 Song P, Hai Y, Ma W, Zhao L, Wang X, Xie Q, Li Y, Wu Z, Li Y, Li H. Arsenic trioxide combined with transarterial chemoembolization for unresectable primary hepatic carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e0613. [PMID: 29718867 DOI: 10.1097/MD.0000000000010613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
554 Altman AM, Coughlan A, Shukla DM, Schat R, Spilseth B, Marmor S, Hui JYC, Tuttle TM, Jensen EH. Minimally invasive microwave ablation provides excellent long‐term outcomes for otherwise inaccessible hepatocellular cancer. J Surg Oncol 2020;121:1218-24. [DOI: 10.1002/jso.25924] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
555 Grégory J, Créquit P, Vilgrain V, Boutron I, Ronot M. Published trials of TACE for HCC are often not registered and subject to outcome reporting bias. JHEP Rep 2021;3:100196. [PMID: 33490934 DOI: 10.1016/j.jhepr.2020.100196] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
556 Bouazza F, Poncelet A, Garcia CA, Delatte P, Engelhom JL, Galdon MG, Deleporte A, Hendlisz A, Vanderlinden B, Flamen P, Donckier V. Radioembolisation and portal vein embolization before resection of large hepatocellular carcinoma. World J Gastroenterol 2015; 21(32): 9666-9670 [PMID: 26327775 DOI: 10.3748/wjg.v21.i32.9666] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
557 Chang Y, Jeong SW, Young Jang J, Jae Kim Y. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E8165. [PMID: 33142892 DOI: 10.3390/ijms21218165] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
558 Gordic S, Ayache JB, Kennedy P, Besa C, Wagner M, Bane O, Ehman RL, Kim E, Taouli B. Value of tumor stiffness measured with MR elastography for assessment of response of hepatocellular carcinoma to locoregional therapy. Abdom Radiol (NY) 2017;42:1685-94. [PMID: 28154910 DOI: 10.1007/s00261-017-1066-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
559 Lin CY, Liu YS, Pan KT, Chen CB, Hung CF, Chou CT. The short-term safety and efficacy of TANDEM microspheres of various sizes and doxorubicin loading concentrations for hepatocellular carcinoma treatment. Sci Rep 2021;11:12277. [PMID: 34112836 DOI: 10.1038/s41598-021-91021-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
560 Uchino K, Obi S, Tateishi R, Sato S, Kanda M, Sato T, Arano T, Enooku K, Goto E, Masuzaki R. Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. J Gastroenterol. 2012;47:1152-1159. [PMID: 22438097 DOI: 10.1007/s00535-012-0574-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
561 Güney İB. HCC Locoregional Therapies: Yttrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT). J Gastrointest Cancer 2017;48:276-80. [PMID: 28634672 DOI: 10.1007/s12029-017-9973-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
562 Reichman TW, Bahramipour P, Barone A, Koneru B, Fisher A, Contractor D, Wilson D, Dela Torre A, Cho KC, Samanta A. Hepatitis status, child-pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma. J Gastrointest Surg. 2005;9:638-645. [PMID: 15862257 DOI: 10.1016/j.gassur.2004.11.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
563 Willatt JM, Francis IR, Novelli PM, Vellody R, Pandya A, Krishnamurthy VN. Interventional therapies for hepatocellular carcinoma. Cancer Imaging 2012;12:79-88. [PMID: 22487698 DOI: 10.1102/1470-7330.2012.0011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
564 Dendy MS, Ludwig JM, Stein SM, Kim HS. Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions. Liver Cancer 2019;8:326-40. [PMID: 31768343 DOI: 10.1159/000494843] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
565 Young S, Cam I, Gencturk M, Rubin N, D'souza D, Flanagan S, Golzarian J, Sanghvi T. Inflammatory Scores: Comparison and Utility in HCC Patients Undergoing Transarterial Chemoembolization in a North American Cohort. J Hepatocell Carcinoma 2021;8:1513-24. [PMID: 34881208 DOI: 10.2147/JHC.S335183] [Reference Citation Analysis]
566 Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP Jr. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53. [PMID: 27785449 DOI: 10.2147/jhc.s61146] [Cited by in Crossref: 418] [Cited by in F6Publishing: 256] [Article Influence: 69.7] [Reference Citation Analysis]
567 Nawawi O, Hazman M, Abdullah B, Vijayananthan A, Manikam J, Mahadeva S, Goh K. Transarterial embolisation of hepatocellular carcinoma with doxorubicin-eluting beads: single centre early experience. Biomed Imaging Interv J 2010;6:e7. [PMID: 21611067 DOI: 10.2349/biij.6.1.e7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
568 Miura JT, Rilling WS, White SB, Hieb RA, Tutton SM, Patel PJ, Gamblin TC, Hohenwalter EJ. Safety and efficacy of transarterial chemoembolization in patients with transjugular intrahepatic portosystemic shunts. HPB (Oxford). 2015;17:707-712. [PMID: 26172137 DOI: 10.1111/hpb.12433] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
569 Sarpel U, Spivack JH, Berger Y, Heskel M, Aycart SN, Sweeney R, Edwards MP, Labow DM, Kim E. The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib. HPB (Oxford) 2016;18:411-8. [PMID: 27154804 DOI: 10.1016/j.hpb.2016.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
570 Fang T, Xiao J, Zhang Y, Hu H, Zhu Y, Cheng Y. Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment. Quant Imaging Med Surg 2021;11:2837-60. [PMID: 34079746 DOI: 10.21037/qims-20-173] [Reference Citation Analysis]
571 Garlipp B, Bruns CJ. The evidence for resection post-selective internal radiation therapy. Future Oncol 2014;10:49-52. [PMID: 25478767 DOI: 10.2217/fon.14.223] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
572 Zhang Y, Li Y, Ji H, Zhao X, Lu H. Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis. Biosci Trends 2015;9:289-98. [PMID: 26559021 DOI: 10.5582/bst.2015.01089] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
573 Tomonari T, Takeishi S, Taniguchi T, Tanaka T, Tanaka H, Fujimoto S, Kimura T, Okamoto K, Miyamoto H, Muguruma N, Takayama T. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. Oncotarget 2016;7:7207-15. [PMID: 26769852 DOI: 10.18632/oncotarget.6889] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
574 Wang D, Gaba RC, Jin B, Lewandowski RJ, Riaz A, Memon K, Ryu RK, Sato KT, Kulik LM, Mulcahy MF, Larson AC, Salem R, Omary RA. Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinoma. Radiology 2014;272:587-97. [PMID: 24678859 DOI: 10.1148/radiol.14131311] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
575 Kosaka Y, Kimura T, Kawaoka T, Ogawa Y, Amioka K, Naruto K, Yoshikawa Y, Kikukawa C, Suehiro Y, Yamaoka K, Ando Y, Uchikawa S, Morio K, Nakahara T, Murakami E, Takahashi S, Tsuge M, Hiramatsu A, Imamura M, Chosa K, Awai K, Nagata Y, Chayama K, Aikata H. Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein. Liver Cancer 2021;10:151-60. [PMID: 33977091 DOI: 10.1159/000513706] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
576 Qian J, Feng GS, Vogl T. Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol 2003; 9(9): 1885-1891 [PMID: 12970869 DOI: 10.3748/wjg.v9.i9.1885] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 58] [Article Influence: 3.3] [Reference Citation Analysis]
577 Takasu M, Yamagami T, Nakamura Y, Komoto D, Kaichi Y, Tani C, Date S, Kiguchi M, Awai K. Multidetector computed tomography-based microstructural analysis reveals reduced bone mineral content and trabecular bone changes in the lumbar spine after transarterial chemoembolization therapy for hepatocellular carcinoma. PLoS One 2014;9:e110106. [PMID: 25329933 DOI: 10.1371/journal.pone.0110106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
578 Lau WY. Future perspectives for hepatocellular carcinoma. HPB (Oxford) 2003;5:206-13. [PMID: 18332989 DOI: 10.1080/13651820310016779] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
579 Piscaglia F, Ogasawara S. Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. Liver Cancer. 2018;7:104-119. [PMID: 29662837 DOI: 10.1159/000485471] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 9.3] [Reference Citation Analysis]
580 Spada F, Fazio N, Bonomo G, Monfardini L, Vigna PD, Radice D, Boselli S, Orsi F. Hepatic intra-arterial chemotherapy in patients with advanced primary liver tumours. Ecancermedicalscience 2012;6:280. [PMID: 23226162 DOI: 10.3332/ecancer.2012.280] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
581 Jang EH, Kim ET, Choi WS, Gwon DI. Lipiodol brain embolism through right inferior phrenic artery-pulmonary vein shunt after transcatheter arterial chemoembolization. Int J Gastrointest Interv 2018;7:91-3. [DOI: 10.18528/gii170003] [Reference Citation Analysis]
582 Yoo BK, Chen D, Su ZZ, Gredler R, Yoo J, Shah K, Fisher PB, Sarkar D. Molecular mechanism of chemoresistance by astrocyte elevated gene-1. Cancer Res. 2010;70:3249-3258. [PMID: 20388796 DOI: 10.1158/0008-5472.can-09-4009] [Cited by in Crossref: 81] [Cited by in F6Publishing: 57] [Article Influence: 6.8] [Reference Citation Analysis]
583 Nhu QM, Knowles H, Pockros PJ, Frenette CT. Pulmonary complications of transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Respirol 2016; 6(3): 69-75 [PMID: 27904836 DOI: 10.5320/wjr.v6.i3.69] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
584 Jun CH, Ki HS, Lee HK, Park KJ, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK, Rew JS. Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma. World J Gastroenterol 2013; 19(2): 284-289 [PMID: 23345952 DOI: 10.3748/wjg.v19.i2.284] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
585 Chen CS, Zhao Q, Qian S, Li HL, Guo CY, Zhang W, Yan ZP, Liu R, Wang JH. Ultrasound-guided RNA interference targeting HIF-1 alpha improves the effects of transarterial chemoembolization in rat liver tumors. Onco Targets Ther 2015;8:3539-48. [PMID: 26664137 DOI: 10.2147/OTT.S94800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
586 Yeoh KW, Prawira A, Saad MZB, Lee KM, Lee EMH, Low GK, Mohd Nasir MHB, Phua JH, Chow WWL, Lim IJH, Omar YB, Ho RZW, Le TBU, Vu TC, Soo KC, Huynh H. Vinorelbine Augments Radiotherapy in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E872. [PMID: 32260169 DOI: 10.3390/cancers12040872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
587 Guo X, Xu Y, Wang X, Lin F, Wu H, Duan J, Xiong Y, Han X, Baklaushev VP, Xiong S, Chekhonin VP, Peltzer K, Wang G, Zhang C. Advanced Hepatocellular Carcinoma with Bone Metastases: Prevalence, Associated Factors, and Survival Estimation. Med Sci Monit 2019;25:1105-12. [PMID: 30739123 DOI: 10.12659/MSM.913470] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
588 Jang ES, Yoon JH, Chung JW, Cho EJ, Yu SJ, Lee JH, Kim YJ, Lee HS, Kim CY. Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization. J Cancer Res Clin Oncol. 2013;139:635-643. [PMID: 23283527 DOI: 10.1007/s00432-012-1364-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
589 Thillai K, Ross P, Sarker D. Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? World J Gastrointest Oncol 2016; 8(2): 173-185 [PMID: 26909132 DOI: 10.4251/wjgo.v8.i2.173] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
590 Mouli S, Baker JC, Brown DB. Interventional Oncology Service Development. Semin Intervent Radiol 2017;34:182-6. [PMID: 28579686 DOI: 10.1055/s-0037-1601853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
591 Maataoui A, Qian J, Vossoughi D, Khan MF, Oppermann E, Bechstein WO, Vogl TJ. Transarterial chemoembolization alone and in combination with other therapies: a comparative study in an animal HCC model. Eur Radiol 2005;15:127-33. [PMID: 15580507 DOI: 10.1007/s00330-004-2517-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
592 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol. 2015;7:738-752. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
593 Greco G, Cascella T, Facciorusso A, Nani R, Lanocita R, Morosi C, Vaiani M, Calareso G, Greco FG, Ragnanese A, Bongini MA, Marchianò AV, Mazzaferro V, Spreafico C. Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma. World J Radiol 2017; 9(5): 245-252 [PMID: 28634515 DOI: 10.4329/wjr.v9.i5.245] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
594 Dohan A, Barat M, Coriat R, Soyer P. A step toward a better understanding of hepatocellular progression after transarterial embolization. Diagnostic and Interventional Imaging 2022. [DOI: 10.1016/j.diii.2022.01.013] [Reference Citation Analysis]
595 Massani M, Stecca T, Ruffolo C, Bassi N. Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis. Updates Surg 2017;69:67-73. [PMID: 28097502 DOI: 10.1007/s13304-017-0414-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
596 Ierardi AM, Angileri SA, Patella F, Panella S, Lucchina N, Petre EN, Pinto A, Franceschelli G, Carrafiello G, Cornalba G, Sofocleous CT. The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma. Med Oncol 2017;34:11. [PMID: 28008570 DOI: 10.1007/s12032-016-0866-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
597 Sayana H, Yousef O, Clarkston WK. Massive upper gastrointestinal hemorrhage due to invasive hepatocellular carcinoma and hepato-gastric fistula. World J Gastroenterol 2013; 19(42): 7472-7475 [PMID: 24259980 DOI: 10.3748/wjg.v19.i42.7472] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
598 Yamashita N, Izumikawa S, Takagi A, Arakawa H, Wakasawa T, Maruyama A. Preparation and characterization of gelatin sponge millispheres from air-in-water-in-oil-type emulsions. J Mater Sci Mater Med 2009;20:1299-305. [PMID: 19132505 DOI: 10.1007/s10856-008-3681-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
599 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014.122] [Cited by in Crossref: 247] [Cited by in F6Publishing: 251] [Article Influence: 30.9] [Reference Citation Analysis]
600 Kobayashi T, Kawai H, Nakano O, Abe S, Kamimura H, Sakamaki A, Kamimura K, Tsuchiya A, Takamura M, Yamagiwa S, Terai S. Prognostic value of subcutaneous adipose tissue volume in hepatocellular carcinoma treated with transcatheter intra-arterial therapy. Cancer Manag Res 2018;10:2231-9. [PMID: 30100754 DOI: 10.2147/CMAR.S167417] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
601 Ueda T, Murata S, Mine T, Onozawa S, Onda M, Naito Z, Amano Y, Kumita S. Comparison of epirubicin-iodized oil suspension and emulsion for transcatheter arterial chemoembolization in VX2 tumor. ScientificWorldJournal 2012;2012:961986. [PMID: 22489208 DOI: 10.1100/2012/961986] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
602 Xiong F, Cao Y, Guo X, Zhang H, Wang J, Xiong B, Liang B, Zheng C. Improved ADM Penetration Distance and Therapeutic Efficiency in a Rabbit VX2 Liver Cancer Model by Relaxin Infusion Combined with Transcatheter Chemoembolization Through Hepatic Artery. Cancer Manag Res 2020;12:3379-88. [PMID: 32494202 DOI: 10.2147/CMAR.S223993] [Reference Citation Analysis]
603 Zhou ZG, Zheng XR, Zhou Q, Shi M, Zhang YJ, Guo RP, Yuan YF, Chen MS, Lin XJ, Lao XM, Li SP. Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. Chin J Cancer 2015;34:205-16. [PMID: 26058595 DOI: 10.1186/s40880-015-0017-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
604 Dodson RM, Firoozmand A, Hyder O, Tacher V, Cosgrove DP, Bhagat N, Herman JM, Wolfgang CL, Geschwind JF, Kamel IR, Pawlik TM. Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies. J Gastrointest Surg 2013;17:2123-32. [PMID: 24065364 DOI: 10.1007/s11605-013-2348-5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
605 Kim S, Chun M, Wang H, Cho S, Oh YT, Kang SH, Yang J. Bone metastasis from primary hepatocellular carcinoma: characteristics of soft tissue formation. Cancer Res Treat. 2007;39:104-108. [PMID: 19746218 DOI: 10.4143/crt.2007.39.3.104] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
606 Yu JI, Yoo GS, Cho S, Jung SH, Han Y, Park S, Lee B, Kang W, Sinn DH, Paik YH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Park HC. Initial clinical outcomes of proton beam radiotherapy for hepatocellular carcinoma. Radiat Oncol J. 2018;36:25-34. [PMID: 29580046 DOI: 10.3857/roj.2017.00409] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
607 Sellers MT, Huggins S, Kegley K, Pollinger HS, Shrestha R, Johnson MW, Stein LL, Panjala C, Tan M, Arepally A. Multivariate analysis of prognostic factors for survival following doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2013;24:647-654. [PMID: 23384831 DOI: 10.1016/j.jvir.2012.12.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
608 Murata S, Mine T, Sugihara F, Yasui D, Yamaguchi H, Ueda T, Onozawa S, Kumita SI. Interventional treatment for unresectable hepatocellular carcinoma. World J Gastroenterol 2014; 20(37): 13453-13465 [PMID: 25309076 DOI: 10.3748/wjg.v20.i37.13453] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
609 Molla N, AlMenieir N, Simoneau E, Aljiffry M, Valenti D, Metrakos P, Boucher LM, Hassanain M. The role of interventional radiology in the management of hepatocellular carcinoma. Curr Oncol. 2014;21:e480-e492. [PMID: 24940108 DOI: 10.3747/co.21.1829] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
610 Qian J, Vossoughi D, Woitaschek D, Oppermann E, Bechstein WO, Li WY, Feng GS, Vogl T. Combined transarterial chemoembolization and arterial administration of Bletilla striata in treatment of liver tumor in rats. World J Gastroenterol 2003; 9(12): 2676-2680 [PMID: 14669311 DOI: 10.3748/wjg.v9.i12.2676] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
611 Adhoute X, Penaranda G, Raoul JL, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H, Bourlière M. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol 2016; 8(17): 703-715 [PMID: 27330679 DOI: 10.4254/wjh.v8.i17.703] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
612 Shi WK, Zhu XD, Wang CH, Zhang YY, Cai H, Li XL, Cao MQ, Zhang SZ, Li KS, Sun HC. PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT. Cell Death Dis 2018;9:428. [PMID: 29559632 DOI: 10.1038/s41419-018-0435-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
613 Fidelman N. A Leap from TACE to TACE Potentiated by Immune Response Modulation and Angiogenesis Inhibition for Patients with Intermediate-Stage Hepatocellular Carcinoma: LEAP-012 Phase 3 Randomized Control Trial Protocol. Cardiovasc Intervent Radiol 2021. [PMID: 34853874 DOI: 10.1007/s00270-021-03010-0] [Reference Citation Analysis]
614 Huang NC, Kuo YC, Chiang JC, Hung SY, Wang HM, Hung YM, Chang YT, Wann SR, Chang HT, Wang JS, Ho SY, Guo HR. Hepatic angiosarcoma may have fair survival nowadays. Medicine (Baltimore). 2015;94:e816. [PMID: 25984668 DOI: 10.1097/md.0000000000000816] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
615 Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Adv Ther. 2016;33:699-714. [PMID: 27039186 DOI: 10.1007/s12325-016-0324-7] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 11.2] [Reference Citation Analysis]
616 Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19-37. [PMID: 24367230 DOI: 10.2147/hmer.s16316] [Cited by in Crossref: 39] [Cited by in F6Publishing: 132] [Article Influence: 3.9] [Reference Citation Analysis]
617 Artinyan A, Nelson R, Soriano P, Chung V, Retseck J, Reynolds J, Marx H, Kim J, Wagman L. Treatment response to transcatheter arterial embolization and chemoembolization in primary and metastatic tumors of the liver. HPB (Oxford). 2008;10:396-404. [PMID: 19088924 DOI: 10.1080/13651820802356564] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
618 Liu WG, Wang YJ, Ma K, Gao GJ. Hepatocellular Carcinoma With Budd-Chiari Syndrome and Obstructive Jaundice: A Therapeutic Challenge. Am J Ther 2017;24:e631-2. [PMID: 27661754 DOI: 10.1097/MJT.0000000000000513] [Reference Citation Analysis]
619 Liu KC, Lv WF, Lu D, Hou CL, Xie J, Lu YH, Cao QS, Tan YL, Zhang YZ, Liu J. Initial Experience of Drug-Eluting Bead-Transcatheter Arterial Chemoembolization After Lipiodol-Based Transcatheter Arterial Chemoembolization Failure for Patients with Advanced Hepatocellular Carcinoma. Cancer Manag Res 2021;13:7973-80. [PMID: 34703317 DOI: 10.2147/CMAR.S332571] [Reference Citation Analysis]
620 Murata S, Mine T, Ueda T, Nakazawa K, Onozawa S, Yasui D, Kumita S. Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma. ScientificWorldJournal 2013;2013:479805. [PMID: 23606815 DOI: 10.1155/2013/479805] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
621 Facciorusso A, Bellanti F, Villani R, Salvatore V, Muscatiello N, Piscaglia F, Vendemiale G, Serviddio G. Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials. United European Gastroenterol J. 2017;5:511-518. [PMID: 28588882 DOI: 10.1177/2050640616673516] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
622 Eltawil KM, Berry R, Abdolell M, Molinari M. Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre. HPB (Oxford) 2012;14:162-70. [PMID: 22321034 DOI: 10.1111/j.1477-2574.2011.00420.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
623 Burak KW, Thomas MB, Zhu AX. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference. HPB (Oxford) 2010;12:321-2. [PMID: 20590906 DOI: 10.1111/j.1477-2574.2010.00186.x] [Reference Citation Analysis]
624 Seong J. Challenge and hope in radiotherapy of hepatocellular carcinoma. Yonsei Med J. 2009;50:601-612. [PMID: 19881961 DOI: 10.3349/ymj.2009.50.5.601] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
625 Ren Y, Dong X, Chen L, Sun T, Alwalid O, Kan X, Su Y, Xiong B, Liang H, Zheng C, Han P. Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization. Front Oncol 2021;11:582544. [PMID: 33738247 DOI: 10.3389/fonc.2021.582544] [Reference Citation Analysis]
626 Chabrot P, Cardot JM, Guibert P, Bouculat F, Cassagnes L, Léger-Enreille A, Buc E, Dechelotte P, Bommelaer G, Boyer L, Abergel A. Cisplatin pharmacokinetics in nontumoral pig liver treated with intravenous or transarterial hepatic chemoembolization. Cardiovasc Intervent Radiol 2012;35:1467-74. [PMID: 22526107 DOI: 10.1007/s00270-012-0386-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
627 Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Takikawa Y, Suzuki K. Therapeutic efficacy of transarterial chemo-embolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma. World J Gastroenterol 2013; 19(14): 2242-2248 [PMID: 23599651 DOI: 10.3748/wjg.v19.i14.2242] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
628 Shao W, Zhang F, Cong N, Li J, Song J. Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma. Oncol Lett 2014;8:2263-6. [PMID: 25289106 DOI: 10.3892/ol.2014.2512] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
629 Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF, Helmberger TK. [Developments and perspectives in radioablative techniques]. Radiologe. 2007;47:1083-1088. [PMID: 17943265 DOI: 10.1007/s00117-007-1572-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
630 Huppert P. [Transarterial chemoembolization of hepatocellular carcinoma]. Radiologe 2022. [PMID: 35171312 DOI: 10.1007/s00117-022-00972-1] [Reference Citation Analysis]
631 Zhang G, Jiang C, Wang Z, Chen W, Gu W, Ding Y. Dehydroabietic acid derivative QC2 induces oncosis in hepatocellular carcinoma cells. Biomed Res Int 2014;2014:682197. [PMID: 25110686 DOI: 10.1155/2014/682197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
632 Guo N, Miao Y, Sun M. Transcatheter hepatic arterial chemoembolization plus cinobufotalin injection adjuvant therapy for advanced hepatocellular carcinoma: a meta-analysis of 27 trials involving 2,079 patients. Onco Targets Ther 2018;11:8835-53. [PMID: 30573972 DOI: 10.2147/OTT.S182840] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
633 Tsurusaki M, Murakami T. Surgical and Locoregional Therapy of HCC: TACE. Liver Cancer 2015;4:165-75. [PMID: 26675172 DOI: 10.1159/000367739] [Cited by in Crossref: 49] [Cited by in F6Publishing: 60] [Article Influence: 7.0] [Reference Citation Analysis]
634 Ismail A, AlDorry A, Shaker M, Elwekeel R, Mokbel K, Zakaria D, Meshaal A, Eldeen FZ, Selim A. Simultaneous injection of autologous mononuclear cells with TACE in HCC patients; preliminary study. J Gastrointest Cancer. 2011;42:11-19. [PMID: 21046282 DOI: 10.1007/s12029-010-9218-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
635 Davila JA, Duan Z, McGlynn KA, El-Serag HB. Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States. J Clin Gastroenterol 2012;46:71-7. [PMID: 22157221 DOI: 10.1097/MCG.0b013e318224d669] [Cited by in Crossref: 50] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
636 Morshid A, Elsayes KM, Khalaf AM, Elmohr MM, Yu J, Kaseb AO, Hassan M, Mahvash A, Wang Z, Hazle JD, Fuentes D. A machine learning model to predict hepatocellular carcinoma response to transcatheter arterial chemoembolization. Radiol Artif Intell. 2019;1. [PMID: 31858078 DOI: 10.1148/ryai.2019180021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
637 Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: Approaching a personalized care. J Hepatol 2015;62:S144-56. [PMID: 25920083 DOI: 10.1016/j.jhep.2015.02.007] [Cited by in Crossref: 136] [Cited by in F6Publishing: 139] [Article Influence: 22.7] [Reference Citation Analysis]
638 Waked I, Berhane S, Toyoda H, Chan SL, Stern N, Palmer D, Tada T, Yeo W, Mo F, Bettinger D, Kirstein MM, Iñarrairaegui M, Gomaa A, Vogel A, Meyer T, Sangro B, Lai P, Kumada T, Johnson PJ. Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. Br J Cancer 2017;116:448-54. [PMID: 28125820 DOI: 10.1038/bjc.2016.423] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 7.4] [Reference Citation Analysis]
639 Huang XB, Wang XW, Li J, Zheng L, Zhao HZ, Liang P, Dai JG. Are autologous bone marrow stem cell transplantation and transcatheter arterial embolization the best choices for patients with hepatocellular carcinoma and hepatic dysfunction? Report of a case. Surg Today 2012;42:1225-8. [PMID: 22179797 DOI: 10.1007/s00595-011-0107-3] [Reference Citation Analysis]
640 Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C, Pitton MB. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer. 2015;15:465. [PMID: 26059447 DOI: 10.1186/s12885-015-1480-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 8.3] [Reference Citation Analysis]
641 He Q, Kuang AR, Guan YS, Liu YQ. Puncture injection of para-toluenesulfonamide combined with chemoembolization for advanced hepatocellular carcinoma. World J Gastroenterol 2012; 18(46): 6861-6864 [PMID: 23239926 DOI: 10.3748/wjg.v18.i46.6861] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
642 Yamakado K, Hirota S. Sub-classification of intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinomas. World J Gastroenterol 2015; 21(37): 10604-10608 [PMID: 26457020 DOI: 10.3748/wjg.v21.i37.10604] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
643 Johnson PJ. Non-surgical treatment of hepatocellular carcinoma. HPB (Oxford). 2005;7:50-55. [PMID: 18333161 DOI: 10.1080/13651820410024076] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
644 Guo TK, Hao XY, Ma B, Yang KH, Li YP, Li HL, Gu YH, Cai H, Liu YL, Li Y, Zhan WP. Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol 2009;135:1685-92. [PMID: 19536563 DOI: 10.1007/s00432-009-0615-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
645 Solorio L, Wu H, Hernandez C, Gangolli M, Exner AA. Ultrasound-guided intratumoral delivery of doxorubicin from in situ forming implants in a hepatocellular carcinoma model. Ther Deliv 2016;7:201-12. [PMID: 27010983 DOI: 10.4155/tde-2015-0008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
646 Minici R, Ammendola M, Manti F, Siciliano MA, Minici M, Komaei I, Currò G, Laganà D. Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9. Front Pharmacol 2021;12:634087. [PMID: 33897422 DOI: 10.3389/fphar.2021.634087] [Reference Citation Analysis]
647 Lee VH, Leung DK, Luk MY, Tong CC, Law MW, Ng SC, Wong KK, Poon RT, Kwong DL, Leung TW. Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma. Onco Targets Ther 2015;8:3457-64. [PMID: 26640386 DOI: 10.2147/OTT.S92473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
648 Gholam PM, Iyer R, Johnson MS. Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current Evidence. Cancers (Basel) 2019;11:E873. [PMID: 31234476 DOI: 10.3390/cancers11060873] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
649 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases: Marrero et al. Hepatology 2018;68:723-50. [DOI: 10.1002/hep.29913] [78495111110.1002/hep.29913','', '1948-5182')">Reference Citation Analysis]
650 Facciorusso A, Licinio R, Muscatiello N, Di Leo A, Barone M. Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol 2015; 7(16): 2009-2019 [PMID: 26261690 DOI: 10.4254/wjh.v7.i16.2009] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
651 Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol 2014; 20(30): 10223-10237 [PMID: 25132740 DOI: 10.3748/wjg.v20.i30.10223] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
652 Wang C, Wang M, Zhang X, Zhao S, Hu J, Han G, Liu L. The neutrophil-to-lymphocyte ratio is a predictive factor for the survival of patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Ann Transl Med 2020;8:541. [PMID: 32411764 DOI: 10.21037/atm.2020.02.113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
653 Roth GS, Benhamou M, Teyssier Y, Seigneurin A, Abousalihac M, Sengel C, Seror O, Ghelfi J, Ganne-Carrié N, Blaise L, Sutter O, Decaens T, Nault JC. Comparison of Trans-Arterial Chemoembolization and Bland Embolization for the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis. Cancers (Basel) 2021;13:812. [PMID: 33672012 DOI: 10.3390/cancers13040812] [Reference Citation Analysis]
654 Kiefer RM, Hunt SJ, Pulido S, Pickup S, Furth EE, Soulen MC, Nadolski GJ, Gade TP. Relative Initial Weight Is Associated with Improved Survival without Altering Tumor Latency in a Translational Rat Model of Diethylnitrosamine-Induced Hepatocellular Carcinoma and Transarterial Embolization. J Vasc Interv Radiol 2017;28:1043-1050.e2. [PMID: 28495453 DOI: 10.1016/j.jvir.2017.03.037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
655 Gu YK, Luo RG, Huang JH, Si Tu QJ, Li XX, Gao F. Transarterial embolization ablation of hepatocellular carcinoma with a lipiodol-ethanol mixture. World J Gastroenterol 2010; 16(45): 5766-5772 [PMID: 21128329 DOI: 10.3748/wjg.v16.i45.5766] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
656 Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A. A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1129-45. [PMID: 34527608 DOI: 10.2147/JHC.S318865] [Reference Citation Analysis]
657 Lewis AL, Dreher MR. Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy. J Control Release. 2012;161:338-350. [PMID: 22285550 DOI: 10.1016/j.jconrel.2012.01.018] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 7.3] [Reference Citation Analysis]
658 Li L, Liu Y, Li H, Guo X, He X, Geng S, Zhao H, Peng X, Shi D, Xiong B, Zhou G, Zhao Y, Zheng C, Yang X. Rational design of temperature-sensitive blood-vessel-embolic nanogels for improving hypoxic tumor microenvironment after transcatheter arterial embolization.Theranostics. 2018;8:6291-6306. [PMID: 30613298 DOI: 10.7150/thno.28845] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
659 Wu J, Li A, Yang J, Lu Y, Li J. Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study. Onco Targets Ther 2017;10:2761-8. [PMID: 28603426 DOI: 10.2147/OTT.S131022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
660 Jiang TP, Wang LZ, Li X, Song J, Wu XP, Zhou S. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma after transcatheter arterial chemoembolization: Therapeutic response and prognostic factors. Shijie Huaren Xiaohua Zazhi 2013; 21(23): 2349-2354 [DOI: 10.11569/wcjd.v21.i23.2349] [Reference Citation Analysis]
661 Xiao YD, Paudel R, Liu H, Zhang B, Ma C, Zhou SK. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging: A potential utility for the evaluation of regional liver function impairment following transcatheter arterial chemoembolization. Oncol Lett 2015;9:1191-6. [PMID: 25663880 DOI: 10.3892/ol.2014.2826] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
662 Yoo BK, Gredler R, Vozhilla N, Su ZZ, Chen D, Forcier T, Shah K, Saxena U, Hansen U, Fisher PB, Sarkar D. Identification of genes conferring resistance to 5-fluorouracil. Proc Natl Acad Sci U S A. 2009;106:12938-12943. [PMID: 19622726 DOI: 10.1073/pnas.0901451106] [Cited by in Crossref: 105] [Cited by in F6Publishing: 104] [Article Influence: 8.1] [Reference Citation Analysis]
663 Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller FH, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L, Lewandowski RJ. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;151:1155-1163.e2. [PMID: 27575820 DOI: 10.1053/j.gastro.2016.08.029] [Cited by in Crossref: 243] [Cited by in F6Publishing: 209] [Article Influence: 40.5] [Reference Citation Analysis]
664 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
665 Elshaarawy O, Gomaa A, Omar H, Rewisha E, Waked I. Intermediate stage hepatocellular carcinoma: a summary review. J Hepatocell Carcinoma. 2019;6:105-117. [PMID: 31372364 DOI: 10.2147/jhc.s168682] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
666 Tong MJ, Rosinski AA, Huynh CT, Raman SS, Lu DSK. Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma. Hepatol Commun 2017;1:595-608. [PMID: 29404481 DOI: 10.1002/hep4.1047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
667 Golla K, Cherukuvada B, Ahmed F, Kondapi AK. Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats. PLoS One. 2012;7:e51960. [PMID: 23284832 DOI: 10.1371/journal.pone.0051960] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
668 Abbadessa G, Rimassa L, Pressiani T, Carrillo-Infante C, Cucchi E, Santoro A. Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib. World J Gastroenterol 2011; 17(19): 2450-2453 [PMID: 21633647 DOI: 10.3748/wjg.v17.i19.2450] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
669 Sun Z, Shi Z, Xin Y, Zhao S, Jiang H, Wang D, Zhang L, Wang Z, Dai Y, Jiang H. Artificial Intelligent Multi-Modal Point-of-Care System for Predicting Response of Transarterial Chemoembolization in Hepatocellular Carcinoma. Front Bioeng Biotechnol 2021;9:761548. [PMID: 34869272 DOI: 10.3389/fbioe.2021.761548] [Reference Citation Analysis]
670 Anaya DA, Blazer DG, Abdalla EK. Strategies for resection using portal vein embolization: hepatocellular carcinoma and hilar cholangiocarcinoma. Semin Intervent Radiol 2008;25:110-22. [PMID: 21326552 DOI: 10.1055/s-2008-1076684] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
671 Zhu M, Jin Z, Hubbard JM. Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. Cancers (Basel) 2021;13:651. [PMID: 33561950 DOI: 10.3390/cancers13040651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
672 Rammohan A, Sathyanesan J, Ramaswami S, Lakshmanan A, Senthil-Kumar P, Srinivasan UP, Ramasamy R, Ravichandran P. Embolization of liver tumors: Past, present and future. World J Radiol 2012; 4(9): 405-412 [PMID: 23024842 DOI: 10.4329/wjr.v4.i9.405] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
673 Rana N, Ju AW, Bazylewicz M, Kallakury B, He AR, Unger KR, Lee JS. Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib. Front Oncol. 2013;3:323. [PMID: 24416722 DOI: 10.3389/fonc.2013.00323] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
674 Mizandari M, Azrumelashvili T, Toria N, Nanava N, Pantsulaia I, Kikodze N, Janikashvili N, Chikovani T. Cured giant hepatocellular carcinoma after transarterial embolization complicated with liver abscess formation. Radiol Case Rep 2020;15:1485-92. [PMID: 32670446 DOI: 10.1016/j.radcr.2020.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
675 Fu J, Wang Y, Zhang J, Yuan K, Yan J, Yuan B, Guan Y, Wang M. The safety and efficacy of transarterial chemoembolisation with bleomycin for hepatocellular carcinoma unresponsive to doxorubicin: a prospective single-centre study. Clin Radiol 2021;76:864.e7-864.e12. [PMID: 34452734 DOI: 10.1016/j.crad.2021.07.013] [Reference Citation Analysis]
676 Bargellini I, Lorenzoni V, Lorenzoni G, Scalise P, Andreozzi G, Bozzi E, Giorgi L, Cervelli R, Scandiffio R, Perrone O, Meccia DV, Boccuzzi A, Daviddi F, Cicorelli A, Lunardi A, Crocetti L, Turchetti G, Cioni R. Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis. Eur Radiol 2021. [PMID: 33871708 DOI: 10.1007/s00330-021-07905-x] [Reference Citation Analysis]
677 Mishra G, Dev A, Paul E, Cheung W, Koukounaras J, Jhamb A, Marginson B, Lim BG, Simkin P, Borsaru A, Burnes J, Goodwin M, Ramachandra V, Spanger M, Lubel J, Gow P, Sood S, Thompson A, Ryan M, Nicoll A, Bell S, Majeed A, Kemp W, Roberts SK; Melbourne Liver Group. Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation. BMC Cancer 2020;20:483. [PMID: 32471447 DOI: 10.1186/s12885-020-06806-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
678 Zhang B, Guo Y, Wu K, Shan H. Intrahepatic biloma following transcatheter arterial chemoembolization for hepatocellular carcinoma: Incidence, imaging features and management. Mol Clin Oncol 2017;6:937-43. [PMID: 28588794 DOI: 10.3892/mco.2017.1235] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
679 Zhang YA, Zhu CW. Management of advanced hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2010; 18(12): 1250-1254 [DOI: 10.11569/wcjd.v18.i12.1250] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
680 Kwan SW, Kerlan RK Jr, Sunshine JH. Utilization of interventional oncology treatments in the United States. J Vasc Interv Radiol 2010;21:1054-60. [PMID: 20478718 DOI: 10.1016/j.jvir.2010.02.028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
681 Chung JC, Naik NK, Lewandowski RJ, Deng J, Mulcahy MF, Kulik LM, Sato KT, Ryu RK, Salem R, Larson AC, Omary RA. Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization. World J Gastroenterol 2010; 16(25): 3161-3167 [PMID: 20593501 DOI: 10.3748/wjg.v16.i25.3161] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]